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I. INTRODUCTION 
Although bovine viral diarrhea (BVD) affects primarily cattle, it 
has been reported in several species of animals from several countries 
in var ious parts of the world. In countries reporting this disease , 
serological evidence usually indicates that a large percentage of 
the cattle have been infected. 
The disease causes considerable economic loss through a variety 
of clinical manifestations . BVD may be an acute disease causing 
severe diarrhea, dehydration , and death. The virus has also been 
associated with abortion, infertility , lameness, respiratory disease 
and decreased milk pr oduction. In some herds the infection is in-
apparent but causes economic losses through reduced feed conversion. 
Ther e is no satisfactory treatment for the disease , but at the 
present time, live attenuated vaccines are used in attempts to pre-
vent the disease. However, there are some disadvantages in using 
t he present vaccines . As long as "live" vaccines are used it is 
always possible that the virus could spread to susceptible pregnant 
animals and cause abortion . It i s also possible that such vaccines 
could revert to a mor e virulent form by successive passages through 
a series of susceptible animals. The present vaccines are not 
presently recoI!llllended for use in pregnant animals or very young 
animals . The incidence of "adverse reactions" and "vaccination 
breaks" which may resemble the acute mucosal disease syndrome is 
not great enough to cause large economic losses in general, but 
i ndividual livestock ovners may sustain losses large enough to 
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discourage fUrther use of the present vaccines. Over a period of time 
this could result in large numbers of nonvaccinated and susceptible 
herds. We have learned through experiences with other diseases, such 
as hog cholera, that eradication or control programs may not be 
successf'U.l as long as attenuated vaccines are used. 
Completely inactivated vaccines have been used successfully for 
the prevention of a number of viral diseases such as: poliomyelitis, 
parainfluenza, Newcastle disease, rabies, African horse sickness, 
hog cholera, and equine encephaJ.omyelitis. 
Because of the disadvantages of the present BVD vaccines and 
because inactivated viral vaccines have been us~d successfUlly 
against other diseases, this study was initiated in an effort to 
develop a.nd evaluate three experimental inactivated vaccines. The 
results of these efforts are the basis for this thesis. 
... 
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II. REVIEW OF LITERATURE 
A. Description of the Disease 
1. Clinical manifestations 
The clinical manifestations of BVD have been well described by 
t he early workers , Olafson~ al. (1) in 1946 , Ramsey and Chivers (2) 
in 1953, Pritchard (3) in 1955 , and Gillespie and Baker (4) in 1959. 
Infected animals usually develop varying degrees of anorexia. Diarrhea 
may vary from a mild form of short duration to a persistent , severe 
bloody type with marked dehydration; however, all infected animals 
do not have diarr hea . Many times respiratory symptoms may be the most 
obvious si~n of illness . There is usually a diphasic body temperature 
elevation (103° - 107°) and an accompanying leukopenia (2 , 000 - 5 , 000 
leukocytes per cubic millimeter) . Often there is an excess nasal 
dischar~e , salivation and lacrimation . Lactating cattle may also 
have a marked decrease in milk production . 
Erosions and ulcers of the oral mucosa, muzzle and nostrils are 
quite connnon in the field cases. Sometimes erosions and ulcers may be 
found on the coronet and in the interdigital spaces of t he feet . 
Less cormnon clinical signs such as: encephalitis, Schipper~~· 
(5 ), cloudiness of the cornea, Rams ey and Chivers (2) and Schipper 
~~ .. ( 5) , and according to Shope (6) hyperkeratosis may also be 
a ssociated wi th the disease . Olafson (1) reported that abortion may 
occur up to 3 months after the dams become infected , and in some cases 
clinical si~ns of the disease were not observed . 
d 
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Lambert (7), using a low passage NADL strain of BVD virus, experi-
mentally infected calves and produced acute diarrhea and death in 
neonatal calves. 
From 1953 to 1 961 it was thought that mucosal disease as described 
by Ramsey and Chivers (2) and the virus diarrhea described by Olafson 
and Rickard (8) and Gillespie and Bak.er (4) were distinctly different 
diseases, but in 1961 Gillespie ~al . (9) reported the antigenic 
relationship between various strains of viral diarrhea virus and the 
mucosal disease virus . 
2. Necropsy findings 
Ramsey (10) described in detail the gross pathology and histo-
pathology of the disease. Lesions of the mucosa of the alimentary 
tract a.nd lamina epithelia are primarily erosive, ulcerative, and 
cystic. Necrosis of the lymphoid tissue of the intestines , lymph 
nodes and spleen is common. Hemorrhages in the epicardium are often 
present . The mesenteric, cervical and retropharyngeal lymph nodes 
may be enlarged and hyperemic. The trachea and lungs usually appear 
normal but occasionally pneumonia may accompany the disease according 
to Olafson~ al. (1) and Ramsey and Chivers (2 ). 
Tyler and Ramsey (11) found that several different BVD iso-
lates produced similar pathological changes in the tissues and cells 
of experimentally infected calves. 
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B. Virus Characterization 
1. Virus isolation 
Bovine virus diarr hea-mucosal disease (BYD-MD) virus can usually be 
isolated f r om a variety of tissues , secr etions and excretions . Lambert 
(7) isolated the v i rus f r om feces , nasal mucous , leukocytes , milk , cecum , 
kidneys , small intesti ne , spleen , and mesenter ic lymph nodes. Mills 
~~· (12) recovered the virus from the urine of infected animals and 
felt that urine could be another means of spreading the disease in a herd . 
2. Nucleic ac id 
There is agreement amon,g; nearly all BVD-MD workers that the 
nucleic acid is ribonucle i c acid (RNA) , Hermodsson and Dinter (13) , 
Ditchfi eld and Doane (14 ) , r.utekunst (15) , and Fernelius (16) . 
3. Size and mor pholoBY 
Virolo~ists do not a~ree on the size and morphology of the BVD- MD 
virus . The variations may be a result of the various methods used 
to determine size and morpholo~ . 
Hermodsson and Dinter (13) using Milli-pore filter s found that 
C24V virus would readily pass the 100 mu filter and r educed amounts 
Of virus would pass the 50 mu filter . Using the electr on microscope 
they reported C24V virus to be spherical with a diameter of appr oxi-
mately 40 mu . 
Gutekunst (15) using NADL-MD and C24V viruses with Millipor e 
filte r s found both viruses passed the 220 mu and the 100 mu filter , 
a small fraction of both viruses passed the 50 mu filter , but no 
i nfective virus passed the 10 mu filter. 
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Ditchfield and Doane (14) using the electron microscope to ob-
serve ultra thin sections of tissue culture cells infected with C24V 
or MAC-A BVD-MD viruses observed particles 150 to 250 mµ in size vith 
projections of 10 mµ. The internal component was in the form of a 
helix with a diameter of 18 mµ and on this basis they suggested that 
the BVD-MD virus is a myxovirus . 
Pritchard (17) published an electron micrograph (supplied by 
Kniazeff ) of BVD virus- like particles 35 to 55 mµ in diameter and 
roughly spherical in form. 
Dutta ~al. (18) in 1964 using negative staining techniques 
reported the virus to be spherical vith a diameter o f 75-85 mµ . The 
central core was enveloped and the outer coat had surface projections 
7-8 mµ in length with bulbous ends. The virus appeared to have 
helical symmetry thus resembling a myxovirus. 
According to Fernelius (16), various strains of BVD-MD viruses 
vary in size. Some strains show a reduction of 3 logs in titer a~er 
passing a 220 mµ filter. The C24V virus, stored 3 1/2 years at -75 C, 
had a titer of 103 after passing a 10 mµ Millipore filter . Using 
the electron microscope and negative staining, he found four types of 
Particles present in the tissue culture fluids: (1) rectangular 
shaped particles 15-20 mµ in size often surrounded by a membrane, which 
rnay have been part of the cellular endoplasmic reticulum; (2) 45- 50 mµ 
Particles; (3) 80 mµ particles; (4) 100-120 mµ particles . Using 
magnification up to 500,000 diameters, he could not detect internal 
structures or external morphological features that could be used for 
virus identification or classification, although he did find 100 mµ 
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?articles with membrane-like structure possessing projections similar 
:o those of a myxovirus. Fernelius also noted that the 100 mu 
particle seemed to break up and release 30-40 mu particles . The 15-20 
mu particles were thought to be soluble antigens or viral precursor 
units . 
4. Ether sensitivity 
Ether sensitivity is one of the major criteria used in viral 
classification and in 1961, Feldman and Wang (19 ) found that viruses 
sensitive to ether were also sensitive to 5% chloroform when incu-
bated at room temperature for 10 minutes. 
Hermodsson and Dinter (13), Gillespie ~ al. (20), and Gutekunst 
(15) reported BVD- MD viruses are ether and chloroform sensitive. 
5. Thermal i nactivation and cationic stabili ty 
A number of investigators have reported results of thermal in-
activation under a variety of conditions. 
Underdahl~ al . (21) and Ditchfield and Doane (14) reported 
BVD- MD viruses were inactivated at 50 c , but Grat zek (22) noted a 
dec reased titer of one log (of C24V) in 24 hours at 37 C or 27 C. 
At 58 C he noted a two component curve which indicated the possibility 
of heat resistant variants . 
Dinter (23) r eported no cationic stabilizat i on of the virus , but 
Gutekunst (15) found 1 M solut ions of either ca++ or Mg++ actually 
enhanced thermal inactivation of NADL-MD virus incubated at 50 c . 
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6. Trypsin sensitivity 
In 1958, Cheng (24) found that trypsin, chymotrypsin or papain 
vould inactivate both the hemagglutinin and infectivity of group B 
arboviruses but they had no appreciable effect on the group A arbo-
viruses . Dinter (23) found C24V BVD virus to be moderately sensitive 
to the enzymatic action of trypsin and thought this virus resembled 
the group B arboviruses and according to Gutekunst (15), both NADL-MD 
and Oregon C24V were moderately sensitive to trypsin. 
7. Infectious RNA 
Diderholm and Dinter (25) in 1966 reported cold phenol extrac-
tion of infectious RNA from BVD virus. These authors inferred that 
these results precluded a myxovirus classification because myxoviruses 
are refractory to extraction of infectious nucleic acid according to 
Schaffer (26) . 
Fernelius (16) tried to extract infectious RNA from NADL-PK22 
strain of BYD using phenol but was unsuccessful. His findings were 
contrary to those of Diderholm and Dinter (25) . 
8. Sedimentation coefficient 
The sedimentation coeffic ient of C24V virus, according to 
Hermodsson and Dinter (13), was estimated to be 80- 90 S by centrifU-
gation in a Spinco Model L centrifUge . 
9. Specific gravity 
Fernelius (16) using isopycnic centrifUgation with sucrose, 
potassium tartrate, and cesium chloride gradients found that the NADL 
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virus had a density of 1.15 gm/ml, with cesium chloride giving the 
sharpest peak. 
10. pH Stability at 56 C 
Gutekunst (15) found that at a pH of 5 the NADL-MD virus was 
inactivated in 45 minutes. At a lower pH it was inactivated more 
rapidly. Between pH of 6 and 7 the virus was not completely inact i -
vated in 2 hours. 
11. Hemagglutinins 
Gutekunst (15) reported that BVD-MD viruses did not cause 
hemagglutination of bovine, chicken, day-old chicken, guinea pig, 
rabbit, mouse, sheep, swine , hamster and human type 0 erythrocytes. 
12 . £ytopathic effect 
According to Gillespie and Baker (4) and Gutekunst (15) the 
NY-1 , Indiana 46 , Sander, Merrell and CG1220 strains are noncyto-
pathogenic. 
Underdahl et ~· (21) isolated and propagated cytopathogenic 
viruses from field cases of MD. They were designated M-833 and 
ISC-1. At 7-10 days PI vacuolization of the EBK cells was noted. 
The vacuoles increased in size until the cell layer was destroyed 
by 10 to 14 days . Gillespie et al . (27) also isolated a virus 
designated Oregon C24V, which was cytopathogenic. Gutekunst (15) 
found that the NADL strain of BYD-MD virus was another cytopatho-
genic BVD- MD virus . 
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13. Growth cycle 
The work of Gratzek ( 22 ), Gillespie et al . (20) , and Gutekunst 
(15) indicates that absorbtion of the virus to cells is accomplished 
in 10-60 minutes. Cell-e.ssociated virus may be detected in 8- 10 
hours and virus in the extracellular fluid 4 hours later . Cytopathic 
effect may be noted in 18 hours but maxim.al CPE and virus titer ma.y 
take 3- 7 days . 
Virus release is gradual rather than rapid as in polio or 
bacteriophage release. 
C. Serology 
Prior to 1960, the relationship between the various BVD and MD 
isolates was unclear , but in 1960 Gillespie et al. (27) showed the 
Oregon C24V virus was antigenically related to New York l and I ndiana 
46 viruses . 
Kniaze!f and Pritchard (28) using plaque assay procedure to con-
duct neutralization tests on 45 various antiserums from the United 
States and England against Oregon C24V virus found that there was a 
serologic relationship between all of the anti-BVD and anti-MD serums 
tested. They also showed that antiserums to bluetongue, hog cholera , 
IBR , bovine infectious ulcerative stomatitis , winter dysentery, 
malignant catarrhal fever, sporadic bovine encephalitis and bovine 
rnycotic stomatitis did not neutralize the C24V virus. Kniazeff et al . 
(29) also reported C24V virus was neutralized by antiserwns against 
BVD- MD viruses from Scotland and West Germany . 
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Gillespie et al. (9) showed several BVD- MD viruses were r elated 
and suggested serological tests be used before any new disease entities 
were postulated on the basis of clinical and pathological findings. 
Using anti NADL-MD serum against 100 TCID50 of various viruses , 
Gutekunst (15) showed an antigenic relationship between NADL- MD 
virus and Oregon C24V , New York 1 , Indiana 46 , Sander , Merrell , and 
CG-1220 BVD v iruses . Gutekunst did not find any antigenic relation-
ship between NADL-MD virus and IBR , PI - 3 , hog cholera , TGE, gr oup B 
arbovirus , and LCM viruses when he used the serum virus neutraliza-
tion tests. 
Gutekunst and Malmquist (30) found that infective NADL BVD- MD 
virus f ailed to fix complement , but the soluble antigen did fix 
complement . 
Gratzek (22 ) in 1962 reported a virus interference test for non-
cytopathogenic BVD-MD vi ruses using VSV for the challenge virus . 
This vas a significant finding because noncytopathogenic BVD- MD 
viruses are difficult to detect and assay in the laboratory. 
Gillespie ~al . (31 ) reported a plaque inhibition assay method 
for detecting noncytopathogenic BVD- MD viruses based on the inter-
ferenc e principle . 
Gutekunst and Malmquist (30 ) repor ted that cells infected with 
noncytopathogenic BVD- MD viruses had almost 100% interference to 
infection with NADL-MD virus. 
Inaba et al . (32) described the use of the END method to detect 
noncytopathogenic BVD viruses . 
4 
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Darbyshire (33) reported that the agar double-diffusion technique 
could be used as a serological technique for diagnosis of BVD-MD . 
The antigenic relationship between BVD- MD virus and hog cholera 
virus causes one to wonder if BVD-MD virus may have evolved from HC 
virus. It was almost inevitable that some workers would try to 
immunize swine by injecting them with BVD-MD virus. 
Beckenhauer !:!_al. (34) found that pigs inoculated vith some 
strains of BVD-MD virus withstood challenge with virulent hog cholera 
virus . They concluded that this immunity was related to antibody 
formation rather than some interference mechanism. 
Darbyshire (35) in 1 962 , using a gar double-diffusion plates, was 
probably the first to report direct evidence of an ant igenic relation-
ship between BVD-MD virus and hog cholera virus . 
Sheffy et !:l• (36 ) showed an antigenic relationship between hog 
cholera and BVD- MD virus using calves and pigs and concl uded that the 
cross protection was a result of accelerated secondary response induced 
by prior exposure to the heterotypic virus. 
Snowdon and French (37) reported that Australian swine may have 
swine fever - neutralizing antibodi es as a result of previous BVD-tvm 
infection . They exposed pigs to 4 strains of BVD-MD virus and found 
that 3 o f the 4 s trains could induce protection against subsequent 
SF challenge . 
Tamoglia et al. (38) in 1965 , tried to use New York-1 strain of 
BVD- MD virus to protect pigs against challenge with HC virus and found 
that it would not protect as well as modified live virus hog cholera 
.. ---------------------------,.........-
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vaccine. It would not meet the licensing requirements for either a 
modified live virus vaccine or an inactivated hog cholera vaccine . 
Mengeling et al. (39) demonstrated antigenic relationship between 
BVD and HC viruses using i.mmunofluorescence and Fernelius (40) used 
immunofluorescence to detect and titrate various BVD-MD viruses . 
Gutekunst and Malmquist (41) found that the soluble antigen 
formed a single line of precipitation in the agar double-diffusion 
plates against the homologous immune serum; however , the infective 
virus "pellet" failed to form a precipitin line. 
Gutekunst and Malmquist (30) infected animals with BVD-MD 
soluble antigen and demonstrated complement-fixing antibodies to the 
soluble antigen and showed that the soluble antigen alone was anti-
genic in calves. 
Fernelius and Packer (42 ) in 1969 r eported that rabbit antisera 
to bovine kidney cells neutralized several strains of BVD-MD virus. 
Antisera to porcine kidney cells did not neutralize BVD-MD virus, even 
when the BVD-MD virus had been grown in porcine kidney cells. A degree 
of specificity was present because the anticellular serum failed to 
neutralize viruses of infectious bovine rhi notracheitis, vesicular 
stomatitis, bovine enterovirus , vaccinia, and parainfluenza-3 . 
D. Immunization Against BVD-MD 
1. Attenuat ed v accines 
In 1954, Baker et a.l . (43 ) adapted BVD-MD virus to rabbits and 
af t er 75 serial passa~es , t he virus was attenuated . Inoculation of 
r 14 
the seventy- fifth passage into susceptible calves produced a slight 
leukopenia and temperature elevation that lasted for one day and the 
calves were protected ap,ainst cballen~e with a virulent virus. 
Baker~ al. (44) in 1958 successfully immunized 6 calves 
against leptospirosis, virus diarrhea and infectious bovine r hino-
tracheitis with a single inoculation of combined vaccine . The 
BVD-MD virus had been attenuated by 80 serial transfers in rabbits . 
The virus did not spread to contact controls . 
York et al . (4 5) in 1960 inoculated some cattle with a rabbit -
adapted modified live virus and others with a bovine kidney tissue 
culture modified live virus . Both vaccines were capable of stimu-
latin~ a protective immune response . Vaccinated animals withstood 
challenge with a virulent BVD-MD virus which sickened the non-
vaccinated controls . In a field test where natural challenge occurred 
there was a significant de~ee of protection . 
Coggins ~al. (46) made 32 serial passages of the Oregon C24V 
strain of BVD-MD virus in primary embryonic bovine kidney (EBK) cells . 
The virus, when used as a vaccine, immunized susceptible cattle and did 
not produce si~ns of clinical illness . 
In 1965 Malmquist ~al. ( 47) adapted the NADL strain of BVD-MD 
virus to both a primary and a subculturable cell line of swine kidney 
cell cultures . They also r eported that ho~ cholera virus would inter-
fere with the cytopathic effect and the yield of the cell-adapated NADL 
strain of BVD-MD virus . 
In 1967 , Marcus and Moll (48) adapted the NADL strain of BVD-MD 
virus to the Madin- Darby bovine kidney (MDBK) cell line by first 
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makin~ 6 passages in bovine testicle cell cultures. The virus pro-
duced CPE in MDBK cells 3 to 5 days after inoculation . 
Bittle ~ al . (49) reported the modification of the C24V strain 
of BVD-MD virus by ser ial passage in primary bovine kidney tissue 
culture . Tests at the 31st passage level indicated the vir us was 
attenuated and did not spread to contact control animals . The vac-
cine strain vas further developed by additional serial passages of 
the virus in tissue culture . 
Bittle and York (50) using a commercially available bivalent vac-
cine composed of attenuated IBR and BVD- MD viruses demonstrated com-
patibility of the viruses . Animals vith antibodies present against 
one of the viruses did not interfere with produc t ion of antibodies 
against the second v i r us . Ninety- six percent of the susceptible 
cattle developed antibodies against BVD- MD virus and 97 % of the sus-
ceptible animals developed antibodies a~ainst I BR . Trivalent vac-
cines using attenuated IBR , BVD-MD and PI - 3 viruses tested in the 
l aboratory and in the field apparently reduced morbidity and did not 
spread to contact control animals . 
Gutekunst ( 51) in 1968 reported that the NADL strain of BVD-MD 
virus adapted to porcine kidney c ells by Malmquist~ al . (47 ) vas 
a t t enuated by 20 additional passages in porcine kidney cells . When 
inoculated into colostrum-deprived calves , it did not produce signs of 
illness nor infect contact control animals . The virus vas inununogenic and 
no adverse reactions vere detected . 
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At the pre3ent time the NADL and Oregon C24V strains of BVD- MD 
virus are the only ones used as seed virus for attenuated BVD-MD 
vaccine production. 
Primary and tertiary EBK cells have been the most commonly used 
cell cultures for graving and attenuating the virus; however, primary 
EBK cells may carry noncytopathogenic BVD-MD virus and contaminate 
vaccines vi.th a virulent strain of virus . To prevent such contamina-
tion, cells must be checked by fluorescent antibody techniques or 
interference tests . The trend is now towards the use of tertiary 
EBK cells, MDBK cells or porcine kidney cells in attempts to get uni-
form cells that are free of adventitious viruses . 
BVD-MD attenuated vaccines are commercially available as mono-
valent, bivalent or trivalent vaccines. It is usually used in combi-
nation with IBR or IBR and PI-3 vaccines. 
2. Postvaccinal reactions 
The subject of postvaccinal reactions is controversial among those 
persons invoived in BVD-MD research, vaccine production and sales, prac-
ticing veterinarians, and livestock owners . 
Peter~~· (52) in 1967 reported the results of their efforts 
to characterize BVD-MD postvaccinal conditions . The study included 
cattle from 23 herds which had a MD-like condition develop 10-20 days 
a~er BVD-MD vaccination. The condition was very similar t o the field 
form of acute MD . Death usually occurred in 10 to 14 days after the 
first signs of illness. Morbidity rates ranged from 0 .2% to 40.0% 
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with an average incidence of 5.2%. It was estimated that 75.0% of 
the cattle that developed severe clinical signs of the disease 
eventually died . 
Calves with clinical signs of the postvaccinal condition had 
no significant antibody titer while calves that were apparently re-
covering from the postvaccinal condition usually had a titer in excess 
of 1:64 . The BVD-MD negative calves did , however, have titers 
against IBR. 
After disc ounting contaminating viruses, prior exposure to BVD-MD, 
simultaneous vaccination with IBR vaccine, and stress , they concluded 
that the probable cause was failure of the immune response against 
vaccine or field strains of BVD-MD virus . 
These workers also detected slight differences between the 
lesions of MD and the postvaccinal condition. With the postvaccinal 
condition the skin , foot , and eye lesions are more common and the 
erosions in the digestive tract are more diffuse and superficial . 
Kirkpatrick (53) observed no higher percentage of herds or 
animals with postvaccinal conditions with combination vaccines than 
with monovalent BVD-MD vaccines. He felt that reactions were from 
the lack of ability of a few animals to respond to the antigen . 
Rosner (54) reported that according to his findings in 1965, the 
morbidity rate for mucosal disease in commercially vaccinated cattle 
was only 1 per 35,700 head vaccinated . In several suspected cases 
of postvaccinal reactions other viruses were isolated. He suggested 
that postvaccinal reactions could be reduced by vaccinating before 
I 
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and at weaning time, before calves leave their native herd and are 
exposed to outside infection. 
Brown and Ramsey (55) , commenting on Rosner's report (54), indi-
cated the incidence of reactions in Iova surpassed the level of Dr. 
Rosner 's "reported" cases. Brown's and Ramsey's figures were based 
on Peter 's (52) 'Wark. They also mentioned that the possibility of 
virus spreadin~ from vaccinates to susceptible animals must be con-
sidered. 
FuJ.ler (56) stated that the incidence of postvaccinal reactions 
was not high enough to warrant disuse of the vaccine, but it 
was high enough to warrant credence and that a presumption of IBR or 
BVD-MD infection prior to vaccination is not a completely satisfactory 
explanation in such cases. 
According to Peacock (57) there is a definite indication that in 
some cases attenuated BVD~\ill vaccine may be a predisposing factor or 
possibly the primary cause of severe reactions. The low morbidity 
and hi~h mortality su~p.ested to Peacock that an individual hyper-
susceptibili ty or immunologic unresponsiveness may be involved in 
postvaccinal reactions. Because BVD-MD virus had been found in IBR 
vaccines, the standard requirements for BVD-MD and IBR vaccines were 
amended to provide more sensitive in vitro tests for extraneous 
viruses in cell culture systems. 
Halper (58) sug~ested that immune serums containin~ BVD-MD anti-
body should not be used at the time of vaccination because of probable 
effects of the antibody on immunop,enesis of BVD-MD vaccine. He recommended 
delaying vaccination for 3 weeks if animals had been given antiserum. 
.. -------------------------------
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Clark (59) reported seeing 40 cases of postvaccinal reactions in 
1000 vaccinates over a 3-month period. Cytopathogenic BVD-MD viruses 
were isolated at necropsy from some of these cattle . 
Clark (60) reported t~e results of his study of the occurrence 
of postvaccinal reactions in 92 , 621 vaccinated animals . One hundred 
and seventy-eight were diagnosed clinically as having MD and 162 died. 
Ten percent of the cattle were checked serologically and only 2 of 18 
had BVD-MD antibodies and these had a titer of only 1:4. There was 
no significant difference in the incidence of reactions when BVD-MD 
vaccines were used alone or when used in combination with IBR vaccine . 
Clark's studies confirmed the findings of others that the postvaccinal 
reactions occur in those few animals that fail to develop antibodies 
against BVD-MD virus. There appeared to be no difference between 
Herefor d and Angus breeds in susceptibility to reactions although 
steers seemed to be slightly more susceptible than heifers . 
Some investigators advocate the use of bovine antiserum alone or 
with vaccine in the BVD-MD immunizing procedures in attempts to pro-
vide immediate protection and avoid possible postvaccinal reactions . 
Simonyi et al. (61) used antiserum prepared against the Oregon 
C24V strain of BVD-MD virus to prevent and treat BVD-MD. Calves 
inj ected I.V . or subcutaneously with 50-100 ml. of 1:512 titer serum 
were protected against challenge while those injected with lower 
titered serum were not protected. Sick animals treated with anti -
serum had a recovery rate of 72% and mortality rate of 6 . 2% while 
40.5% of the untreated controls recovered and 25 . 2% died. 
.. --------------------------------~ 
20 
Si.monyi ~al . (62) attenuated the C24V BVD- MD vir us by serial 
passage in ~K cells before using the virus as a vaccine . They 
reported that occasional vaccinates evidenced mild signs of the 
disease, some vaccinated animals excreted virus , and contact con-
trols dev eloped a low antibody titer against BVD- MD v irus . It was 
further observed that 18 weeks a~er the second vaccination some 
animals wer e no longer protected against challenge . They r eported that 
the monthly weight ga ins of vaccinated animals were higher than that 
of the controls . They r ecommended immunizing newborn or diseased 
calves with immune serwn alone or immune serum plus vaccine followed 
by a second dose of vaccine 4 weeks later. 
Lambert !:.!. al . (63) reported that a prophylactic dose of concen-
trated homologous bov ine antiserum administered simultaneously with 
IBR-BVD vaccine did not interfere with active immunization . They 
felt that cattle vacc inated with serum and vaccine could be protected 
by the serum until they could develop an active immunity. 
Lambert et al (64) us ing concentrated bovine antiserum from 
cattle given repeated injections of Pasteurella multocida , Pasteurella 
homolytica, Corynebacterium pyogenes, IBR , BVD and PI- 3 found that 
20 cc of antiserum inoculated subcutaneously into neonatal calves re-
duced the morbidity and mortality rates of pneumonia-enteritis in 
newborn calves . 
E. Inactivated Vaccines 
Attenuated vaccines will always be popular because they are rela-
tively inexpensive to make and have been effective against a number of 
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di seases. Inactivated vaccines have also been used successf'Ully to 
control a number of viral diseases such as: poliomyelitis, rabies, 
Newcastle disease, parainfluenza, African horse sickness, bog cholera, 
and equine encephalomyelitis. 
A number of physical and chemical agents are currently used to 
inactivate virus: heat, ultraviolet irradiation, phenol, formalin, 
beta- propiolactone (RPL), and acetylethyleneipiine (AEI) being some of 
the more common. 
1. Beta-ProPiolactone inactivated (BPL) vaccines 
In 1955, LoGrippo and Hartman (65) reported the results of screen-
ing over 600 physical and chemical agents in their search for a more 
satisfactory agent for preparation of inactivated virus vaccines . 
They found that BPL was capable of inactivating viruses in 10-15 
minutes at 37 c, whereas formalin and phenol required days for in-
activation of virus. Satisfactory inactivated vaccines wer e prepared 
with viruses of eastern equine encephalomyelitis, rabies and the MM 
strain of murine encephalomyelitis. BPL had not been used previously 
in the preparation of vaccines. The antigenicity of the BPL vaccines 
vas better than the formalin or phenol-inactivated vaccines. They 
also found that 2 to 4 times the minimal effective viricidal concen-
tration of BPL can be used without critical loss of antigenicity. 
LoGrippo (66) reported that BPL-inactivated biologicals are non-
t oxic because BPL is completely degraded and the products of hydrolys i s 
are non- toxic. He also found that a combination of BPL and ultra-
viol et ( U. V.) light i s better t han BPL alone because less BPL is 
22 
required. There is less alteration of the protein and less tailing 
effect of the inactivation curve. 
One of the more widely used BPL-inactivated vaccines has been NDV 
vaccines . Mack and Chotisen (67} in 1955 demonstrated the immuno-
genicity of the vaccine and this report stimulated much interest in 
the development of BPL-inactivated Newcastle disease virus (NDV) 
vaccines . 
Gill~~· (68) studied the effects of aluminum hydroxide, 
ethylene glycol and phosphorylated hesperiden as adjuvants with BPL-
inactivated NDV vaccine and found that all 3 gave similar results. 
Hofstad (69) evaluated 6 commercial inactivated NDV vaccines. 
The chickens were injected at 6 weeks of age and challenged with 
virulent virus 6 weeks later . Two of the vaccines were considered 
inferior . 
Hofstad (70) used the B1 , GB, and Manhattan strains of NDV for 
his vaccine production. In his first experiment the viruses were 
inactivated with formalin and the B1 vaccine provided the best 
immunity . In the second experiment BPL was used to inactivate the 
viruses and there was no significant difference in the immunogenicity 
of the 3 strains . The BPL-inactivated vaccines seemed to produce 
better immunity than formalin-inactivated vaccine. Hofstad concluded 
that the inactivating substance, the adjuvant, and t he type of virus -
bearing material are more important than the particular strain of virus 
used or the route of inoculation. 
Chang ~al. (71) compared six strains of BPL- inactivated New-
castle disease virus in chickens. The immune response was measured 
... 
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oy the level of hemaP,~lutination inhibition antibody. Virulence appeared 
to be unrelated to antigenicity as the Texas GB, Kansas-Manhattan, and Bl-
Hitchner strains induced significantly hip;her HI antibody levels than 
~J-LA Sota , Mass-MK-107, and California 11914 strains . All chickens 
gave an anamnestic response followin~ the second inoculat ion . 
Stone and Boney (72) used NDV antigen-antibody complexes to 
vaccinate 2-day-old chicks with different levels of passive immunity . 
They concluded that immunological refractoriness of congenitally 
immune chicks could be overcome by vaccination with antigen-antibody 
complex vaccine. 
Stone et al . (73) immunized young chickens against NDV with BPL-
killed-NDV ad.ministered in the drinkin~ water. Although this method 
Of vaccination saves time and labor it requires a large amount of 
antigen . 
Winterfield (74), using a BPL-inactivated i nfectious bronchitis 
virus (IBV) that is used successfully in Great Britain, could not 
detect formation of significant neutralizing antibodies against 
Massachusetts 41 and Beaudette IBV strains. When the chickens were 
challenged they all developed severe respiratory signs. No dif-
ference could be noted between vaccinated chickens and the unvaccinated 
controls. 
Price and Thind (7 5) found that BPL-inactivated Langat E5 virus 
injected into mice induced production of protective levels of neutral-
izinp; antibodies but did not induce production of serum protective-
factor (SPF). Live virus induced the production of both SPF and 
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neut ralizing antibodies . Mice with no detectable neutralizin~ anti -
bodies were protected against challenge with virulent virus if they 
bad the SPF . 
Pilchard (76) evaluated 10 experimental inactivated hog cholera 
vaccines and found that a Bordetella-azo-BPL-inactivated-virus hog 
cholera vaccine and an endotoxin-BPL- inactivated-virus hog cholera 
vaccine induced immunity in 7 days . Other inactivated hog cholera 
vaccines require 2 inoculations and the induction of immunity takes 
2 to 3 weeks . 
Mirchamsy and Taslimi (77) evaluated both formalin- and BPL-
inactivated African horse sickness (AHS) virus vaccines and found 
that these vaccines protected horses for at least 6 months . The 
virus was ~rovn on monkey kidney cells . The formalin- inactivated 
product induced sli~htly higher neutralizing antibody titers . 
Fellowes (78 ) found that 0 . 05% BPL did not completely inactivate 
foot - and-mouth disease virus; however, 10 minutes exposure to u.v. 
li~ht prior to BPL t reatment did completely inactivate the virus . 
The immuno~enicity of either the AEI or the U. V.-BPL-inactivated 
products was approximately the same . 
Chloroform has not been used widely as an inactivatin~ agent. 
However , Walker ~ al . (79) in 1946 reported on the development of a 
satisfactory chloroform- inactivated rinderpest virus vaccine . The source 
of the virus was lymph nodes , spleen and lungs from infected calves 
that had been febrile for 2 or 3 days . Chloroform appeared to be 
superior to formalin as an inactivatin~ apent. They recommended a 
.,.. 
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single 20 cc dose ad.ministered subcutaneously for use under field 
conditions . 
Rouhandeh et al . (80) found that ether- inactivated IBR virus could --
be reactivated when resuspended in water containing insoluble inor ganic 
compounds which adsorbed the virus and adhered to cells , thus pro-
viding a cell entry mechanism for the damaged virus . This finding of 
reactivation may cast doubt on the rationale of ether or chlorofor m 
inactivation which in theory may be based on blocking the cell attach-
ment or cell entry of the virus . 
2 . Viral-component vaccines 
Rec ent work with s ome of the viruses infecting man has shown that 
viral pr otein subunits can stimuliate pr oduction of neutralizing anti-
bodies and may be used as vaccines . Such products might avoid side 
effects caused from certain other components of the virus . 
Crick and Brown (81) treated r abies vi rus with "Tween"-ether 
and then inactivated the residual infectivity with AEI . Subunits 
which were separated by sucrose density gradien~ centrifugation and 
inoculated into mice induced protective levels of neut ralizing anti-
bodies . This indicated that viral subunits may be useful in rabies 
vaccination . 
Brown~ al . (82) separated 3 fractions of VSV by sucrose 
density gradient centrifugation. All 3 fractions were then inacti-
vated v i th AEI. The inactivated fractions vere immunogenic i n guinea 
pigs . 
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Davenport (83) reported that the antigenicity of formalin-
inactivated influenza HA-vaccines was almost equal to that of whole 
virus vaccines if AlP04 was used as an adjuvant vith the inactivated 
vaccine . 
In 1964, Kasel ~al . (84) vaccinated human volunteers with non-
infectious soluble antigens of adenovirus type 1 . The vaccine in-
duced production of neutralizing antibodies and follo\.Ting challenge , 
the immunized volunteers had a significant reduction in virus shed-
ding and almost complete protection against illness. 
Norrby et al. (85) compared a measles HA vaccine vith a formalin-
killed vaccine . Both vaccines produced 100% serological conversions 
and HI antibodies vere detectable l year after vacc ination. Tvo 
mild cases of measles occurred among children given the formalin-
killed vaccine but none occurred in those given HA vaccine . 
, 
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III. MATERIALS AND METHODS 
A. Preparation of Vaccines 
1. Virus 
The bovine viral diarrhea virus used in this study was the NADL-MD 
strain which has been previously described by Gutekunst (15). This 
virus was isolated from several tissues of a naturally ..occurring 
fatal case in a group of yearling Holstein-Friesian heifers at the 
National Animal Disease Laboratory in 1962. The seed virus used 
in this wor k was the second passage in pr imary embryonic bovine 
kidney (EBK) cells. 
2. Tissue culture system 
Primary EBK cell cultures were used throughout the entire experi-
ment. Cell cultures were prepared by the general method of Younger 
(86) as modified by Gutekunst (15) . Kidneys were collected aseptically 
from selected bovine fetuses in the sixth to ninth month of develop-
ment and placed in a sterile container of Hank's balanced salt solu-
tion (HBSS) . The capsule was r emoved from the kidney and the cortical 
region separated from the medulla. The cortical tissue was minced 
until pieces were approximately one cubic millimeter in size . The 
l 
minced cortical tissue was washed three times with cold GKN solution , 
with the washing fluids being discarded . The tissues were placed in 
2 
a sterile trypsinization flask containing a sterile Teflon covered 
1see Appendix for formula . 
2
Bellco Glass Company , Vineland, New Jersey . 
r.'lli~n~tic stirrin~ bar. Sterile trypsin solution (0 . 25 percent) chilled 
to 4 C was added to the trypeinization flask and incubated at 4 C for 
4 to 6 hours . Af'ter incubation the supernatant fluid which contained 
toxic debris was discarded and fresh cold trypsin was added . Trypsini-
zation was continued for an additional 18 hours at 4 c. Following 
t r ypsinization, fibrous tissue was separated f r om the trypsinized 
cells by filtration through sterile cheesecloth . The cells were 
sedimented by centrifugation at 1,000 RPM in a refrigerated centrifuge 
and the supernatant fluid was discarded . The cells wer e then washed 
three times with cold GKN and diluted in HBSS conteinin~ 10% specific -
patho~en-free (SPF) calf serum to ~ive a final concentr ation of 
6 
approximately 1 X 10 cells/ml. The EBK cells were then propaRated 
in sterile tissue culture tubes . The cells were planted in medium 
containin~ 89 . 5% HBSS , 0 . 5% lactalbumin hydrolysate, 10 . 0% SPF calf 
serum , and penicillin and streptomycin at a concentration of 100 
units and 100 ~~/ml , respectively . After three days ' incubation at 
37 c, the medium was replaced with 89 . 5% Earle's balanced salt solu-
tion (EBSS), 0 . 5% lactalbumin hydrolysate , 10% SPF calf serum, and 
antibiotics . 
After complete monolayers had formed (approximately 5 days), the 
medium was removed and EBSS medium with 5% SPF calf serum was added 
for maintenance . 
3 . Preparation of virus suspension for vaccines 
TW'enty- four 500 ml Blake bottles of primary EBK cells were treated 
with 10 ml of 0 . 21. EDTA for 30 minutes at 37 C to facilitate removal of 
the cells. 
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The cells were washed with Earle's medium, centrifuged at 800 RPM , 
supernatant fluid removed and resuspended in 100 ml of HBSS with 10% SPF 
calf serum. Cell suspensions were then transferred into 24 two- liter 
roller bottles and rotated at 12 RPR at 37 C. 
After 48 hours the medium was replaced with EBSS containing 0 . 0 5% 
lactalbumin hydrolysate (LAH) and 10% SPF calf serum . 
Seventy- two hours later the medium was removed and the roller 
bottles with EBK monolayers were inoculated with 10 ml of a second 
passage NADL BVD- MD virus in Earle's medium. The roller bottles were 
allowed to rotate for l hour at 37 C , then 90 ml of Earle's with 0.5% 
LAH plus 5% SPF calf serum was added to the roller bottles. In 96 
hours the cultures were harvested and clarified by centrifugation at 
19,000 RPM (53 , 700 x G) in a Beckman Model L-2 ultracentrifuge . 
4. Virus t itrat ion 
The NADL strain of BVD-MD virus is cytopathogenic so its presence 
could be detected by CPE in EBK cells . The virus suspension was 
quantitated by titrations of infectivity in susceptible c ells by 
10-fold serial dilutions in EBSS, then 0 . 2 ml. of each dilution was 
inoculated into each of 4 roller tubes containing monolayer s of EBK 
cells. The cultures were incubated at 37 C and observed for appear-
ance of CPE after 7 days. The 50% end points were calculated by the 
method of Reed and Muench (87) . 
5. Beta- nroniolactone inactivation 
The inactivation by BPL was carried out with some modifications 
of the methods described by LoGrippo and Hartman (65). The solution 
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of BPL (97%) stored at 4 C was slowly mixed with virus suspension 
to a final concentr ation of 0 . 2%. The pH of the virus suspension was 
adjusted to 8 . 0 with lM potassium dihydrogen phosphate before the 
addition of BPL. The pH of the mixture was periodically adjusted 
to 7. 4 during the 20-minute incubation per iod at 25 C. Samples wer e 
taken for in vitro tests for residual virus . 
Ten ml Rehsorptar2 (aluminum hydroxide gel) was added to 90 ml 
of the BPL- inactivated vaccine to give a final concentration of 10% . 
Each lot of vaccine was shaken vigorously for 2 hours on a mechani cal 
shaker and distributed into 50 ml vials, sealed, labeled and stored 
at 4 C till used. 
6. Chloroform inactivation 
One hundred ml of chloroform was added to 1900 ml of the virus 
suspension . The mixture was incubated for 96 hours at 4 C in a 
sterile flask and s t irred continuously with a Teflon cover ed magnetic 
stirring bar . Following incubation the chloroform was sedimented by 
centr ifugation at 1500 RPM for 20 minutes in a refrigerated centri-
fuge. The supernatant fluid was saved . This sedimentation pr ocedure 
was repeated 3 times . 
The residual chloroform was removed by bubbling filtered air 
throu~h the inactivated virus suspension for 12 hours. 
1wilmot Castle Company , Rochester, New York. 
2
Reheis Chemical Company , Chicago, Illinois . 
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At this time samples were taken for in vitro tests for any re-
maining infectivity. Ten ml of Rehsorptar was added to each 90 ml of 
chloroform- inactivated vaccine to give a final concentration of 10%. 
After vigorous shaking each lot of vaccine was distributed into 50 
ml vials, sealed, labeled, and stored at 4 C until used . 
Approximately 1 500 ml of the chloroform-inactivated virus , 
without adjuva.nt, was saved for the preparation of the soluble 
antigen vacc ine . 
7. Soluble anti5en vaccine 
Chloroform- inactivated virus suspension was first concentrated 
approximately 10-fold by dialysis against polyethylene glycol 
1 
(Carbowax 20-M) . Carbowax was then removed by dialysis a gainst 
distilled water for 16 hours at 4 C. 
The concentrated inactivated virus suspension was then centri-
fuged in a Spinco model L-2 HV ultracentrifuge at 220 , 000 g for 16 
hours in a cesium chloride (CsCl) density gradient system. Five ml 
of concentrated inactivated virus suspension was layered on each of 
the CsCl density gradient tubes which were prepared by layering 5 ml 
of a 20% CsCl solution on 2 ml of 35% CsCl solution . A~er centri-
fu~ation the gradient ranged from approximately 1 . 02 to 1 . 34 g/ml as 
determined by an Abbe 31 refractometer. 
Preliminary experiments using infectious virus indicated that the 
infectious portions of the suspension are in those fractions of the 
1union Carbide Corporation, New Yor k , New York. 
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density gradient between 1.02 and 1.20 g/ml. The soluble antigens, 
as determined by agar gel double-diffusion methods, were in the 
gradient between 1.20 and 1.34 g/ml. . 
The soluble antigen-containing fractions from 12 tubes were pooled 
and dialyzed against distilled water for 8 hours followed by dialysis 
against 0 . 975% phosphate buffered saline (PBS) for 16 hours. 
A sample of the vaccine was saved for agar gel double-diffusion 
tests and the remainder vas divided into 9 .0 ml aliquots, placed in I 20 ml vaccine bottles containing l ml of Rehsorptar, and stored at 4 C 
until used for animal experiments. 
8. In vitro test for residual infectivity 
Before the 3 experimental vaccines were inoculated into_calves , 
20 ml from each 100 ml lot of vaccine was checked for infectious virus 
by inoculating 0 . 2 ml of vaccine into each of 100 roller tubes con-
taining monolayers of EBK cells. Prior to inoculation , each roller 
tube of cells was examined to make sure all cells appeared normal . 
Seven days a:rter inoculation cells were examined for evidence of CPE 
and at that time 0 . 2 ml of fluid from each tube was transferred to 
another tube of fresh EBK cells. If , after 4 such passages , all 100 
tubes were negative for CPE the vaccine was considered free of infec-
tious virus. 
After 4 passages there was no CPE in any of the 300 tubes of EBK 
cells and all 3 vaccines were considered free of r esidual infective 
NADL strain of BVD-MD virus . 
.................. ----------------------~~ 
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B. Animal Exper imentation 
I n order to obtain enough calves and to be reasonably sure that 
exper imental calves were free of BYD- MD virus and antibodies , it was 
necessary to obtain calves by 2 methods . Twelve calves were obtained 
from the NADL BYD- negative herd and 11 calves were collected from a 
BVD- positive herd by using a modified SPF technique and depriving t he 
calves of colostrum . Eight of the 11 calves were f rom BYD- positive dams . 
1. SPF calves 
The ~roup of 11 Holstein- Friesian calves was obtained by means 
of the following modifi ed SPF technique . At the time of parturition 
the placenta was incised and manipulated to minimize or eliminate 
contact between the calf and t he birth canal of the dam . Calves were 
taken from the dam and put into ster ile galvanized steel cans , then 
delivered immediately to an isolated barn at the research laboratory . 
The calves did not receive colostrum , but were fed synthetic milk 
without antibiotics until two months old . After two months the calves 
wer e weaned by gr adually changing their ration from synthetic milk 
and calf concentrate to a complete built- in roughage (BIR) ration . 
At appr oximately 3 months of age the calves were transferred to 
another isolation barn for the experiment . At that time they were 
divided i nto three ~roups of 3 calves each and one ~oup of 2 calves. 
Each ~roup of calves was kept in a separate r oom fo r the duration 
of the experiment . During the experiment all personnel showered and 
chan~ed clothes before entering the barn in order to avoid the possi-
bility of carrying infectious a~ent s from outside sources to the 
r 
experimental animals . These calves were used in experiments 1 , 2 , 3 , 
and 7 as outlined in Figure 1 and tested BYD-negative prior to vacci-
nation . 
2. Naturally born (NB) calves 
The gr oup of 12 Holstein-Friesian calves from serologically BVD-
negative dams was assembled from the NADL BYD- negative her d . These 
calves were born naturally and all owed to suckle in order to obtain 
the benefits of colostrum. These calves were later fed commercial 
mi.Lt. replacer and concentrate according to manufacturer's directions . 
At 2 months of age they were veaned and put on BIR rations in the 
same manner as the SPF calves. At approximately 3 months of age they 
were moved to the isolation barn, tested , divided i nto 4 groups vith 
3 animals in each group , and handled in the same manner as described 
for the SPF calves . 
3. Plan of animal exnerimentation 
The immunogenicity of the soluble antigen vaccine (SA), the 
chloroform- inactivated vaccine (ChJ.) , and the BPL-inactivated vac-
cine (BPL) was evaluated in SPF and in NB calves . In each group , 2 
calves served as vaccinates and l calf served as a contact control . 
;,i1 vaccinates were ~iven 2, 5-ml intramuscular injections of vaccine . 
The first inoculation was given when the calves were approximately 4 
months of age and the s econd inoculation was given 4 weeks later . Con-
tact control calves were not vaccinated . 
One hundred eighty- two days after the second inoculation all 
vaccinates and contact controls were challenged with an intravenous 
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inoculation of 10 ml of tissue culture fluid containing approximately 
7 10 CCID50 per ml of the third passage NADL strain of BVD- MD virus . 
The barn control animals , 6120 and 6104 in experiment 7 , vere chal-
lenged by an intraocular instillation of virus into each eye. Animals 
6127 and 6128 , in exper iment 8, were challenged by spraying approxi-
ma.tely 1 ml of viru~ suspension into each nostril and calf 6114 va.s 
given 10 ml of the challenge virus orally . The postvaccination and 
postchallenge r esponses of the calves were studied from clinical , 
serologic , immunologic and pathologic aspects. The methods of 
measuring these responses will be described later . 
Tvo SPF calves and 3 NB calves served as barn controls. These 
calves vere used to detect any possible BVD-MD contamination during 
the experiment . These animals were not vaccinated but were challenged 
at the same time as the vaccinates and contact controls . Their re-
sponse to challenge virus was to serve as a basis for comparison with 
that of the vaccinated calves. 
1. Clinical 
C. Procedures for Evaluating Post-Vaccination 
and Post-Challenge Responses 
Pre- vaccination and pre-challenge temper atures were recorded daily 
for 14 days before the calves vere vaccinated and challenged , and post -
vaccination and post-challenge body temperatures were also recorded 
daily for at least 14 days . 
All experimental calves were observed daily for evidence of clinical 
signs of illness such as anorexia, nasal discharge, excessive lachrymation 
Experiment Type Colostrum Calf number Vaccine used 
number of birth 
l SPF Deprived 6119 , 6123 , SA 
6121 None (contac t control) 
2 Natural Permitted 6086 , 6ll6 , SA 
6071 None (contact control) 
3 SPF Deprived 6098, 6099 , Chl 
6066 None (contact control) 
4 Natural Permitted 6105 , 6102 Chl 
6o87 None (contact contr ol) 
5 SPF Deprived 6060 , 6080 , BPL w 0\ 
6088 None (contact control) 
6 Natural Permitted 6097 ' 6100, BPL 
6106 None (contact control) 
7 SPF Deprived 6120 , 6104 None (barn cont r ol) 
8 Natural Pennitted 6114 , 6127, None (barn control) 
6128 
Figure 1. Precis of an imal experiments 
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and salivation, listlessness , diarrhea , constipation, le..meness and for 
evidence of lesions on the tongue, gums, dental pad , muzzle , lips , and 
ha.rd palate • 
2. Laboratory 
a . Hematology Blood samples were collected from each calf f or 
leu.kocyte counts. Several pre- vaccination and pre-challenge samples 
were obtained and the post-vaccination and post-challenge bleeding 
schedule was as follows: daily samples for 14 days , followed by veekly 
samples until challenge . Samples of blood were collected in 10% 
ammonium and potassium oxalate in sterile 10 ml tubes . The anticoagulant 
and the blood were mixed thoroughly and taken immediately to the 
laboratory for leukocyte counts. After the leukocyte count vas made 
the remainder of the sample vas used for virus isolation . 
b . Virolo~y Pre- vaccination, post-vaccination, pre-challenge 
and post-challenge samples of blood for virus i solation were collected 
at various times in 10 ml tubes containing 10% ammonium and potassium 
oxalate solution . Samples were immediately placed i n a PR- 2 refri-
gerated centrif\lge1 and spun at 2000 RPM for 50 minutes . After the 
plasma had been pi petted off , the leukocytes were ca.rfully removed 
with a Pasteur pipette . Approximately 0 . 2 ml of leukocytes was 
inoculated into each of 4 tubes of primary EBK cell cultures . The 
inoculated cultures were incubated at 37 C and were observed daily 
for evidence of cytopathic effect (CPE ) . When CPE was not apparent, 
1
International Equipment Company , Boston, Massachusetts . 
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the fluids were subcultured into 4 additional tubes of primary EBK 
cell cultures and observed daily for 7 days for evidence of CPE. Virus 
isolations were considered negative when at least 3 passages were ma.de 
on EBK cells and there was no CPE. 
At various times before and after vaccination and cha.1.lenge nasal 
secretions were collected with cotton swabs and examined for the 
presence of BVD virus in the secretions. As these samples were ob-
tained they ver e placed immediately into EBSS and stored at - 20 F 
until examined . Approximately 0.2 ml of this solution was inoculated into 
each of 4 t ubes of primary EBK cell cultures. These were likewise in-
cubated at 37 C and observed daily for evidence of CPE and con-
sidered negative when at least 3 passages were made on EBK cells and 
there was no CPE. 
Rectal s\18.bs were also taken from each experimental animal at the 
identical intervals as for collecting nasal secretions . Samples 
were placed in EBSS containing antibiotics and stored at - 20 F until 
inoculated into primary EBK cell cultures . Maximwn storage time be-
fore examination was 6 days . Inoculation and incubation of primary 
EBK cell cultures was similar to the procedures described for nasal 
swabs . 
c. Serolo5Y Blood samples for serologic studies were collected 
at identical times to the blood collection schedule described pre-
viously. 
The serum neutralization test was used to study the antibody re-
sponses of the cattle . The beta method of constant virus and varying 
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serum dilutions was used . Test sera were heat-inactivated in a 
56 C water bath for 30 minutes . Serial 4-fold dilutions of each 
serum to be tested were prepared in 1. 0 ml of EBSS . An equal amount 
of EBSS containing approximately 100 ccrn50 per ml of NADL-MD virus 
~as added to the serum dilutions . The mixtures were incubated at 
37 C for one hour and then 0 . 2 ml of each serum-virus mixture was 
inoculated into each of 4 tubes containing primary EBK cell cul-
tures . The cultures were incubated at 37 C and observed daily for 
evidence of cytopathic effect for 7 days . The antibody titer was 
expressed as the recipr ocal of the dilution giving CPE in 50% of 
the tubes. 
' 
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IV. RESULTS 
A table for each animal , listing the recorded body temperature, 
leukocyte counts , antibody titers , signs of illness , and r esults of 
attempted virus isolations may be found in the appendix . Graphs 
showing the serologic response , temperature, a nd leukocyte count 
for each animal appear in Figures 2 through 24 . 
None of the control animals developed detectable neutralizing 
antibodies against BVD-MD virus before being challenged with vi r ulent 
virus; however , all of these animals developed relatively high titers 
after challenge. 
Following the first inoculation of vaccine , 9 of the 1 2 calves 
developed a low level of BVD antibodies but 3 calves failed to 
develop detectable levels of antibody. A~er the second inoculation , 
a strong secondary serologic response was detected in all vaccinates . 
A~er challenge, neither the vaccinates nor the control animals 
developed ulcers in the oral cavity that are usually associated with 
the disease . Virus isolation tests were negative for all vaccinates, 
but BVD-MD virus was isolated from all the controls a~er challenge . 
A. Soluble Antigen Vaccine 
l . Experiment 1 (SPF calves) 
Calf 6123 (Figure 2) and calf 6119 (Figure 3) developed l ow anti -
body titers 7 days a~er the fir s t vaccination and peak titers of 
16 , 384 following the second inoculation . A~er calf 6123 was challeneed 
i t had a slight temperature elevation and leukopenia but no clinical 
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signs of disease. Calf 6119 developed a temperature elevation , leuko-
penia and acute signs of illness such as depression , anor exia, and 
respiratory involvement. 
The contact control, calf 6121 (Figure 4), had a mild depression , 
anorexia , and a dry non-productive cough following challenge . One may 
also note that there was a temperature spike of 105 F and a leukopenia . 
2 . Exper iment 2 (NB calves} 
Both vaccinates , 6086 and 6116 (Figures 5 and 6) , developed an 
antibody titer of 8 after the first inoculation and peak titers of 
16 , 384 following the second inoculation of vaccine. Calf 6116 had 
a marked rise in titer following challenge but calf 6086 had only a 
4- fold increase in titer . The body temperature of both calves was normal 
during the entire time of the exper:Unent but calf 6086 developed a 
slight leukocytosis on the ninth day postchallenge while calf 6116 
had a slight leukopenia on the fifth day postchallenge . Neither of 
the vaccinates had clinical signs of illness following challenge . 
Calf 6071 , the contact control , did have a slight temperature 
elevation and leukopenia the third day postchallenge and was anorectic 
and depressed from the third to the fi~h day after r eceiving the 
challenge virus . 
B. Chloroform Inactivated Vaccine 
1 . Experiment 3 ( SPF calves) 
It is interesting to note that neither of the twin calves , 6098 
and 6099 , (Figures 8 and 9 ) developed detectable levels of antibodies 
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a~er the first inoculation of vaccine but did have strong and nearly 
identical secondary responses. Following challen~e neither of the 
vaccinates appeared ill although both had a slight leukopenia and calf 
6098 had a slight temperature elevation on the eighth day postc hallenge . 
The control animal , 6066 (Figure 10), had 2 temperature spikes 
and a diphasic leukopenia; however , the only signs of illness were 
a loss of appetite on the seventh day and a depressed appearance on 
the seventh and tenth day postcha.llenge. 
2 . Experiment 4 (NB calves) 
Calves 6105 and 6102 (Figures ll and 12) both had detectable 
but low levels of antibodies 7 days after the first inoculation and 
both showed a good secondary response to the vaccine. Calf 6105 had 
a leukopenia following challenge but was not clinically ill . Calf 
6102 had a temperature of 107 F and was slightly depressed on the 
ninth day postchallenge . 
The control calf, 6087 (Figure 13), was clinically ill f'rom the 
third throu~h the eighth day postchallenge as evidenced by marked 
depression and loss of appetite. This animal also had a temperature 
elevation on the seventh and eighth day at'ter challenge and a 
leukopenia on the third and seventh day postchallenge . 
C. Beta-Propiolactone Inactivated Vaccine 
1 . Exneriment 5 (SPF calves) 
Calf 6080 (Figure 14) had a typical primary response with a low 
antibody titer and a strong secondary response to the vaccine with 
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a peak titer of 4096. The other vaccinate, calf 6060 (Figure 15) , 
vas the third example of priming as a result of the first inocula-
tion followed by a strong secondary response with a peak titer of 
2048 . Both vaccinated calves remained free of clinical signs of 
disease after challenge and the body temperature and leukocyte count 
remained normal for calf 6080 ; however, calf 6060 did have a slight 
leukopenia for 2 days and a temperature of 105 F for 1 day . 
Calf 6088 (Figure 16) , the contact control, vas ill from the 
second to the seventh day postchallenge as evidenced by depression, 
anorexia, respiratory involvement, laminitis , leukopenia and 
temperature elevation . 
2. Experiment 6 (I'iB calves) 
The primary response of calf 6100 (Figure 17) was not detectable 
until 21 days after the first inoculation but the secondary response 
was prompt and reached a peak titer of 8 ,182 . In spite of a high 
titer of neutralizing antibodies at the time of challenge, the calf 
evidenced signs of depression on the seventh and eighth days post-
challenge and a temperature spike of 104 F occurred on the seventh 
day . A slight diphasic leukopeoia was detected on the seventh and 
ninth days after challenge . 
Calf 6097 (Figure 18) had an antibody titer of only 2 at the 
time of the second inoculation of vaccine, but the titer increased 
to 4096 after 3 weeks. On the seventh day a~er challenge , the calf 
had a mild diarr hea , a temperature of 107 F and a leukopenia . 
,. 
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The contact control, 6106 (Figure 19), appeared depressed from 
the third to the seventh day postcha.llenge, also had diarrhea on 
the sixth and seventh day. Although a rather marked leukopeoia did 
occur on the fourth and sixth days postcha.llenge a body temperature 
elevation was not detected. 
D. Challenge of Barn Control Calves 
1. Experiment 7 (SPF calves) 
Calves 6104 (Figure 20 ) and 6120 (Fi~e 21) were challenged by 
an intraocular instillation of approximately l ml of the challenge 
virus . Both calves were infected as evidenced by the immune response 
to the challenge virus and the appearance of a very mild depression 
following challenge. The clinical signs of illness were almost in-
apparent. Although calf 6104 had an elevated temperature and leuko-
penia , calf 6120 did not. 
2 . Experiment 8 (NB calves) 
Calf 6127 (Figure 22) and calf 6128 (Figure 23) were challenged 
with l ml of virus sprayed into each nostril and calf 6114 (Figure 24) 
was given 10 ml of the virus orally . All three calves developed peak 
BVD antibody titers of 4096 in 5 t o 6 weeks. 
Calves 6127 and 6128 became clinically ill a~er challenge as 
evidenced by depression, anorexia and a transient respiratory involve-
ment. Calf 6127 had a temperature elevation and leukopenia and 61 28 
had a leukopenia but no temperature spike was detected . Calf 6128 did 
have diarrhea on the second and t hird day a~er challenge . 
Of the 23 calves used in the entire experiment, calf 6114 developed 
the most acute signs of illness. It had a severe diarrhea vi.th flecks 
of blood, dehydration, loss of appetite and was depressed . It also 
had a dipha.sic leukopenia with concurrent temperature spikes . 
Figure 2. Calf 6123 , an SPF calf, vaccinated IM with SA vaccine and challenged IV 
rith third EBK passage NADL strain of BYD virus . The graph shows 
neutralizing antibody titer of the serum, body temperature and l eukocytes 
per cmm . of blood. 
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Figure 8. Calf 6098, an SPF calf, was vaccinated IM with Chl vaccine and challenged IV 
with third EBK passage NADL strain of BVD virus. The graph shovs neutralizing 
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Figure 10. Calf 6066, an SPF calf, was the contact control with calves 6098 and 6099. 
It did not receive vaccine but was challenged IV with third EBK passage 
NADL strain of BVD virus. The graph shows neutralizing antibody titer of 
the serum, body temperature and leukocytes per cmm . of blood . 
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Figure 11. Calf 6105 , an NB calf , va.s vaccinated IM with Chl vaccine and challenged IV 
with third EBK passage NADL strain of BVD virus . The graph shows neutralizing 
antibody titer of the serum, body temperat ure and leukocytes per cmm . of blood . 
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Figure 16. Calf 6088 , an SPF calf, was the contact control with calves 6060 and 6080 . 
It did not receive vaccine but was challenged IV with third EBK passage 
NADL strain of BVD virus. The graph shows neutralizing antibody titer of 
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Figure 17. Calf 6100 , an NB calf, was vaccinated D4 with BPL vaccine and challenged IV 
with third EBK passage NADL strain of BVD virus. The graph shows neutralizing 
antibody titer of the serum, body temperature and leukocytes per cmm. of blood. 
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Figure 21. Calf 6120 , an SPF calf, was a barn control animal . It did not receive vaccine , 
but was challenged intraocula.rly with third EBK passage of NADL strain BVD 
virus . The graph shows neutralizing antibody titer of the serum, body tempera-
ture and leukocytes per cmm . of blood . 
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but · was challenged intranasally with third EBK passage of tbe NADL strain 
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Figure 23. Calf 6128 , an NB calf, vas a barn control animal. It did not receive vaccine, 
but was challenged intranasa.lly with third EBK passage of the NADL strain of 
BVD virus. The graph shows neutralizing antibody titer of the serum, body 
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V. DISCUSSION 
The results of this research indicate that all 3 of the experi-
mental inactivated BVD~ID vaccines are immunogenic in cattle , a s evi-
denced by the induction of high levels of circulating neutr alizing 
antibodies f ollowing the second inoculation of vaccine . Ther e appears 
to be a cor relation between the presence of these antibodies and pro-
tection, as most of the vaccinated calves failed to develop clinical 
signs of illness following c hallenge with low- passage homologous virus . 
It also appears t hat the immunity may last for 6 to 12 months , which 
would be long enough to get most feedlot animals to market . 
In compar ing the three vaccines one may note that the peak anti-
body titer s and the titers at the time of challenge a r e highest for 
the SA- vaccinated cattle . This may be a r esult of the quality of the 
antigen i njected or of a quantitative difference as this vaccine was 
concentrated approxima~ely 10 times prior to the separation of soluble 
antigens by density gradient centrifugation . 
The next best response was found in the calves vaccinated with BPL 
vacc ine and the calves vaccinated with Chl vaccine had the lowest peak 
titer s and the lowest titers at the time of challenge . It would appear 
that , f r om a pr actical point of view, the BPL vaccine would be the best 
one of the 3 for possible commercial production because the SA vaccine 
would be more costly t o produce . 
When comparing the immune response of NB , colostrum- fed calves, 
with the SPF , colostrum-depri ved calves , it was noted that the average 
antibody titer was higher in the NB calves when BPL or ChJ. vaccine was 
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used. When SA vaccine was used the antibody titers were approximately 
the same in both the NB and SPF calves. It may have been either the 
quality or the larger quantity of anti~en in the SA vaccine tba.t evoked 
a better immune response. In the case of calves receiving Chl or BPL 
vaccines the colostrum-fed calves may be more immunologically competent 
than the SPF calves. These findings may not be significant because of 
the small number of calves used. 
Although there were differences in antigenicity between the 3 
vaccines, all 3 vaccines were immunogenic . With each of the vaccines 
used, some vaccinates developed a transitory leukopenia and temperature 
elevation following challenge , but in general, any postcha.llenge clini-
cal signs of illness observed in vaccinates were so slight that they 
would not be noticed under field conditions . The small number of calves 
used precluded the possibility of varying the dosage of challenge virus 
given, therefore, a valid comparison of the relative protection of the 
3 vaccines could not be made . In the challenge pa.rt of the vaccine 
evaluation it was obvious, however, that the vacc inated animals were 
better protected than the controls . 
I t was interesting to note that the control animal , calf 6114 , which 
was al.so the oldest and largest animal , evidenced the most acute signs 
of illness . This animal was also the only animal that was challenged 
orally . Under natural conditions animals are probably infected orally 
or intranasally and the cells lining the respiratory or digestive tract 
may therefore be more readily infected. The resultin~ cellular change s 
could render cells more suscepti ble to subsequent invasion by secondary 
94 
bacteria. The barn controls, 6104 and 6120 , showed t he least clinical 
evidence or illness. This may have been a result of the low dosage 
or virus received because of the i ntraocular route of inoculat i on . 
Perhaps the intravenous r oute of inoculation i s not the most desirable 
route for challenge because the virus is cleared relatively soon by 
the reticuloendothelial system. 
Calf 6119, vaccinated with SA vaccine, developed a high level of 
antibodies but became ill following challenge. The fact that this 
animal became ill was not surprising because this calf had developed 
a chronic respiratory condition prior to the first inoculation of 
vaccine and appeared ill at other times during the experiment. The fact 
that the control calf remained BVD-MD negative until challenge indi-
cates that calf 6119 did not have a BVD-MD infection . Because BVD-MD 
virus was not recovered from this animal during the postchallenge 
period , it was felt that the primary cause of illness was probably some 
other agent and that challenge potentiated the effect of the pre-
existing infection. 
One may note that very few of the control animals developed a 
diarrhea while a transitory respiratory involvement was not uncommon 
after challenge . In previous experiments the respiratory symptoms were 
also observed mor e often than diarrhea . This resembles the observations 
i n the field and justifies the inclusion of BVD- MD virus as a cause of 
respiratory disease in cattle . 
The choice of an inactivating agent was not easy becaus e viruses 
may be inactivated by a number of physical and/or chemical methods . It 
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was dec ided t o use chemical inactivation in this experiment because of 
t he narrow range between loss of infectivity and complete denaturation 
when physical methods are used . 
I n the past formalin has been the most widely used chemical in-
activating agent, but more recently it has been shown that comparable 
or better results are obtained by the use of other agents such as BPL, 
a.cetylethyleneimine, and perchloroethylene. Beta-propiolactone was 
used because it was available, easy t o work with, and preliminary tests 
indicated that it could be used successfUlly to inactivate BVD-MD 
virus and maintain some antigenicity. 
Ether or chloroform will inactivate BVD-MD virus and disrupt the 
intact virion releasing soluble antigens . It was decided to use 
chloroform for the inactivating agent for a second vaccine because it 
is easier and safer to work with than ether . The Chl vaccine could 
also be used for prepari ng the soluble antigens following procedures 
used by Gutekunst and Malmquist (41). 
In the SA vaccine the nucleic acids were probably le~ with the 
protein fractions of the virus. With the nucl eic acids pr esent in a 
vaccine there is the possibility of replication taking pl a c e , so in 
fUture production of a soluble antigen vaccine it would be mor e de-
sirable to further purify the vaccine by separating and discarding the 
nucleic acids. 
Earlier experiences with residual virus prompted the use of large 
samples (20%) from each batch of vaccine for testing and the 4 passages 
of vaccine samples on EBK cells without evidence of CPE before con-
sidering the samples free of live virus . 
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Results of an earlier experiment indicated that calves could be 
infected with a Chl vaccine that was mixed with chloroform for only 48 
hours . The vaccine appeared free of residual live virus after 1% of the 
vaccine was passed once on EBK cells without evidence of CPE. 
In a second preliminary test of a Chl vaccine, the virus was mixed 
vith the chloroform tor 96 hours and more extensive in vitro tests for 
residual virus indicated that the vaccine did not contain infective 
virus . Subsequent tests in calves verified the fact that the vacc ine 
wa.s inactivated without complete loss of antigenicity. 
It was observed that EBK cells did not appear normal during the 
first passage of the Chl vaccine. It appears that a very small quantity 
of residual chloroform can affect the condition of EBK cells. The lack 
ot typical. BVD-MD CPE may have been from complete inactivation of the 
virus or from some alteration in the cells. Later tests did show that 
such abnormal appearing cells can be infected by the virus. The fact 
that the second and third passages did not affect the appearance of 
the cells would indicate that the abnormal appearance of the cells 
during the first passa~e was a result of the chloroform rather than 
from virus . The added procedures for removing the residual chloroform, 
the slower inactivation time and the idea that inactivation by chloro-
form may be due only to the action on the outer envelope indicated that 
chloroform was not the inactivating agent of choice. 
Since primary EBK cells were used throughout the experiment there 
was always the possibility of contamination with adventitious non-CPE-
producing BVD-MD viruses . Such viruses might render the EBK cells 
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resistant to infection by the CPE- producing strain of virus being used , 
thereby ~iving false ne~ative tests for residual virus . To guard 
against this possibility all batches of EBK cells were tested for non-
CPE adventitious BVD- MD viruses by use of the interference test using 
NADL str ain of virus to detect the presence of interfering virus . 
In this experiment the inactivated vaccines were tested for infective 
virus before the addition of the adjuvant . In the future, tests should 
be made after the adjuvant is added in order to detect possible re-
activation of the vir us . The adjuvant if complexed vith the virus 
could enhance attachment and entry into the EBK cells or the body cells 
of the vaccinated animal , Rouhandeh ~al . (80) . 
Althou~h the extensive in vitro testin~ indicated the vaccines were 
killed it was ~ratit'ying to note that none of the contact controls 
developed DVD-MD antibody titers prior to challPn~e . The relatively 
veak primary response was further circumstantial evidence that the 
vaccines did not contain residual virus . One mi~ht compare the primary 
response to the vaccines vith the primary r esponse of t he control 
animals to challenp,e virus and note the differences in the curves . The 
first contact with live virus induces a more prompt response vith hi~her 
antibody titers than the first contact with a killed virus . 
Occasional samples of feces and nasal mucous vere collected and tested 
for local BVD-MD neutralizing antibodies. There was no evidence of 
antibodies in the feces but this srunpling vas done late in the experiment 
and such antibodies, if ever present , could have disappeared by the time 
the samples vere taken . 
The nasal mucous :rrom all vaccinated animals did contain a 
neutralizing substance against the BVD-MD virus and it was not present 
in the control animals prior to challenge. This material has not been 
characterized. It was not determined if this substance was produced 
locally or if it was a result of extravasation of serum from the 
capillaries . It was found that the titer of this substance was several 
times higher vhen nasal mucous was collected by the use of tampons 
inserted into the nose and removed 2 to 24 hours later, than if col-
lected by a direct low vacuum aspiration method. Because of the ob-
vious irritation, the tampon method was completely unsatisfactory. 
If these neutralizing substances a.re, in fa.ct, locally produced immuno-
globulins of the IgA class, it would be an interesting finding that 
could contribute to our understanding of the mechanism of protection 
against BVD-MD infection introduced by way of the respiratory route. 
The results of this project indicate that it may be practical t o 
use inactivated BVD-MD vaccines . The duration of immunity is long 
enough but a more prompt induction of immunity would be desirable. 
The time that is required to induce protection might be reduced by 
giving the second inoculation of vaccine sooner, increasing the amount 
of adjuvant used, using a different adjuvant, or increasing the dosage 
of the vaccine . 
Only live attenuated BVD-MD vaccines are commercially available 
and they are usually satisfactory. They have certain advantages over 
killed vaccines, such as: 
1. They induce immunity more promptly . 
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2 . Protection lasts longer . 
3 . They protect against a greater number of strains of the virus . 
4. Local immunity is usually better. 
5. They a.re less expensive to produce. 
6. One inoculation is usually adequate . 
Although live vaccines have some important advantages they also 
have some disadvantages a.nd potential hazards that might be eliminated 
through the use of inactivated vaccines . It has been mentioned earlier 
that killed vaccines have been used successfully against a number of 
animal diseases. Some of the potential hazards that might be eliminated 
are : 
l . Possible reversion to a more virulent fonn . 
2 . Transmission of disease to susceptible animals . 
3. Induction of severe reactions in some vaccinates . 
4. Transmission of adventitious agents. 
5. Induction of abortion in pregnant animals . 
6. Production of fetal abnormalities. 
7. Potential transmission to man . 
8. Stress potentiation of currently existing infection . 
9. Deterioration of vaccine during use or storage . 
10 . The perpetuation of the live virus which could render control 
programs ineffective. 
Although the added cost of production may preclude the general usage 
of these BVD-MD vaccines, t hey could be used to vaccinate valuable pregnant 
animals or very young calves, because the use of the presently available 
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BVD-MD vaccines i s not recommended for such animal s . I f control pro-
grams are ever attempted it might be desirable to use inactivated 
vaccines for a few years t o reduce t he number of possible carriers of 
BVD-MD virus. 
The future acceptance and usage of the inactivated BVD-MD vaccines 
will depend on a number of economic and educational factors as well as 
possible regulations concerning the use of a live vaccine . 
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VI. SUMMARY 
Tbree experimental chemically inactivated vaccines were developed . 
One of the vaccines ""8.S inactivated by BPL, the second by chloroform , 
and the third vas a chl.oroform-inactivated soluble antigen vaccine. 
Al.uminum hydroxide vas used as the adjuvant with all 3 vaccines . 
Large samples (20%) from each batch of vaccine were negative to 
in vitro tests for residual virus . None of the controls developed 
neutralizing antibodies prior to challenge which vas fUrther evidence 
that the vaccines did not contain live virus. 
The i.mmunogenicity of the vaccines vas evaluated in 12 serologically 
BYD-MD negative calves. Each vaccine was tested in 4 SPF , colostrum-
deprived calves and in 4 naturally-born calves that had received 
colostrum. 
All vaccinates were given two 5-ml intramuscular injections of 
vaccine, the first at approximately 4 months of age and the second 4 
weeks later . None of the 6 contact or 5 barn control calves were vac-
cinated . Six months after the second i noculation all calves were 
challenged with a third passage NADL str ain of BYD-MD virus. 
All 12 of the vaccinates developed high titers of circulating 
neutralizing antibodies against BYD-MD virus and the titers persisted 
for at least 6 months. 
Following challenge, 10 of the 11 control animals developed signs 
of illness , body temperature elevation and leukopenia while over 90~ 
of the vaccinates were protected. 
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VII. CONCLUS IONS 
l. All 3 of the experimental inactivated BVD-MD vaccines a.re 
capable of inducing the production of neutralizing antibodies in serolo-
gically negative calves. 
2 . Both BPL and chloroform are suitable inactivating a.gents . 
3 . The duration of immunity induced by these vaccines is at least 
6 months and the antibody titer at this time is still high. 
4. Over 90% of the vaccinates are protected against acute clinical 
BVD-MD a~er challenge with a low passage of the homologous virus . 
5. Folloving the second injection of vaccine all calves had a 
strong secondary immune response. 
6. The SA vaccine induces the highest titers of antibodies . 
7 . The BPL vaccine is more antigenic than the Chl vaccine . 
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X. APPENDIX 

Data f r om calf 6080 (cont i nued) 
Virus Isol at i on from 
Dais TemEer ature Leukocytes Ti ter Nose Rec t um Blood S;;m;Etoms 
49 102 . 4 19 , 900 256 
56 102 .4 20 , 000 2 , 048 
63 102 . 2 19 , 000 4,096 
70 101. 9 1 5 , 000 2 , 048 
77 101.8 17 , 500 2 , 048 
84 102 . 0 1 5 , 000 1,024 
91 102.1 12 , 000 2 , 048 
98 101. 9 16 , 500 2,048 
105 102 . 4 11, 7 50 l,02h 
112 101. 5 16 , ooo 256 
ll9 101.7 1 5 , 200 2 , 048 
126 101.8 16 , 200 2 , 048 
133 1 01. 9 18 , ooo 1,024 
140 101.6 16 ,100 512 
147 101.8 14,750 128 I-' I-' 
154 102 . 0 1 5 , 600 512 <.n 
161 102 . l 16 , 300 1,024 
168 102 .4 17 , 000 1,024 
175 102 .1 15 , 400 512 
208 102 . 0 13 , 000 512 
209 101 . 7 12 , 500 512 
210 101.8 15 , 600 512 
211 102 . 4 18 , 200 256 
212 102 . 6 19 , 500 256 
213 102 . 7 18 , 600 
214 102 . 8 17,000 
215 102 . 9 15 , 400 
216 103. 5 14,ooo 
217 101.8 1 5 , 200 
218 Challenp;ed 101.8 14,200 
Data. from calf 6080 (cont inued) 
Virus Isolation fr om 
Days Temperature Leukocytes Ti ter Nose Rectum Blood Symptoms 
219 102 . 0 12 , 500 256 
220 102 . 0 11,900 
221 101.8 12 , 900 
222 101 . 0 11 , 500 
223 102 . 6 11 , 900 
224 101 . 4 12 , 600 
225 101.8 12 , 000 8 ,192 
226 102 . 0 17 , 250 
227 101.6 17 , 150 
228 101.6 16 , 250 
229 101. 8 16 , ooo 
230 101.8 16 , 200 
231 101. 4 17 , 500 
232 101. 2 16 , 800 65 , 536 
233 101.6 16 , 500 t-' t-' 
237 101 . 2 16 , 250 en 
239 101 . 6 16 ,150 131 , 072 
244 102 . 0 15 , 800 
246 101 . 4 16 , 200 32 ,768 
251 101 . 4 16 , 500 
253 101.4 16 , 400 32 ,768 
258 101. 4 15 , 750 
260 101. 2 14 , 800 131,072 
Data f rom calf 6060 Vaccine - BPL 
Virus Isolation from 
Days Temper ature Leukocytes Ti t er Nose Rect um Bl ood Symptorns 
1 101.0 20 , 000 
2 101.0 14,400 
3 101.9 11,600 
4 101.6 12 ,700 
5 102 . 0 24 , ooo 
6 102 . 6 24, ooo 
7 101.8 1 5 ,800 
8 1 02 . 0 11,600 
9 101.6 15 ,000 
10 101. 5 16 , 250 
11 102 . 4 17 , 000 
12 102 . 0 18 , ooo 
13 102 . 6 13 , 600 
14 Vacc i nated 102 . 0 17,500 
15 101. 9 14 , 300 ...... 
16 101.9 14 ,100 ...... 
'1 
17 102 . 1 13 , 500 
18 102 . 3 13 ,700 
19 101.9 16 , 250 
20 1 01.7 14 , ooo 
21 101.8 11,250 
22 102 . 2 12 , 000 
23 102 . 3 12 ,750 
24 102 .8 13 , 250 
25 102 . 5 14 , 200 
26 102 . 4 14,ooo 
27 102 . 5 13 ,700 
28 102 .7 15 , 500 
35 102 . 0 18 , 500 
42 102 . 5 17,100 
Data from calf 6060 (continued) 
Virus Isolation from 
Days Temperature Leukocytes Titer Nose Rectum Blood Symptoms 
49 102 . 6 21 , 250 256 
56 102 . 4 19, 500 1 , 024 
63 102 . 3 1 5 ,500 2 , 048 
70 101.8 9 , 000 1,024 
77 102 . 5 20,000 512 
84 101.6 22,000 512 
91 102.2 17 , 000 512 
98 101.8 13,000 512 
105 101 . 5 16 , ooo 512 
112 101. 6 16 ,ooo 512 
119 101. 4 15,200 1,024 
126 101. 6 14,700 1 , 024 
133 101.7 i4,ooo 
140 101 . 5 17 , 200 
147 101.9 19 , 500 128 ....... ....... 
154 102 .2 20 , 000 CX> 
161 102 . 3 18 , 200 96 
168 101.9 17 , 800 
175 101.6 16 , ooo 
208 101.8 16 , 500 
209 102 . 0 16 , ooo 128 
210 101.8 17 , 800 128 
211 101. 6 1 5 ,900 256 
212 101 . 9 14 , 500 256 
213 101 . 6 12 , 500 
214 101.5 13 , 600 
215 101.6 14,ooo 
216 101.6 13 , 250 
217 101.0 12 , 700 
218 101 . 5 12 , 500 
Data from calf 6060 (continued) 
Virus Isolation from 
Dals TemEerature Leukocytes Titer Nose Rectum Blood s~Etoms 
219 101.8 16 , ooo 128 
220 101 . 8 12 , 000 
221 101 . 0 7 , 000 
222 102 . 4 7 , 500 
223 100 . 8 11,000 
224 101.6 12 , 800 
225 101.0 10 , 000 8 ,182 
226 105 . 0 17,000 
227 101. 0 18 , 250 
228 101.6 14,100 
229 101 . 4 13,800 
230 101.8 13 , 400 
231 101. 6 1 5 , 000 
232 101. 2 14,700 131,072 
233 101.2 14,300 f-' 
237 101 . 2 14 ,100 f-' lD 
239 101. 4 13 , 900 131,072 
244 101. 2 14,600 
246 101 . 0 15 , 200 8 ,192 
251 101.8 15 , 000 
253 101. 2 14 , 900 131 , 072 
258 101. 2 15 , 600 
260 101.2 14,750 131 , 072 
... 
Data from calf 6087 Vaccine - None 2 Contact Control 
Virus Isolation from 
Dars TemEerature Leukocytes Titer Nose Rectum Blood S~Etoms 
1 102 . 6 i 6 , ooo 
2 101.6 9 , 400 
3 102 . 2 10 , 600 
4 101.6 12 ,100 
5 103 . 3 17 , 300 
6 102 . 0 9,600 
7 102 . 4 10 ,700 
8 102 . 4 14 , 800 
9 103 . 0 19 , 800 
10 101 . 7 12,500 
11 102 .1 12 , 800 
12 102 . 5 13,200 
13 102 . 5 11,400 
14 Vaccinated 102 . 4 13,400 
15 102 .4 11,500 
16 102 . 4 12 , 500 
17 102. 5 11,900 
18 102. 8 10 , 200 
19 101. 8 10 , 400 
20 101. 9 10 , 750 
21 102 . 4 11,800 
22 102 . 6 10 ,100 
23 102.5 10 , 250 
24 102 .7 9 , 900 
25 102 . 6 8 , 750 
26 102 . 4 9 , 800 
27 102 . 6 13 , 000 
28 102 . 4 10 , 500 
35 102. 2 11 , 750 
42 2nd Vacci - 102 . 4 12 , 400 
nation 
Data from calf 6087 (continued) 
Virus Isolation from 
Days TemEerature Leukocytes Titer Nose Rectum Blood Symptoms 
49 102 . 4 11,500 
56 102 . 4 13,000 
63 101.9 1 2 , 250 
70 102 . 0 14, 500 
77 102 . 0 12 , 000 
84 102 . 0 12 , 000 
91 101.5 12 , 500 
98 101. 8 14,600 
105 101. 7 13 , 300 
112 101. 9 11,900 
119 101 . 8 14,ooo 
126 102 . 0 12 , 200 
133 101 .7 11,800 
140 101.8 1 0 , 900 
147 101.7 12,200 f-' 
154 102 . 0 10 , 750 IV f-' 
161 101 . 9 11,400 
168 101.9 10 , 900 
175 101.7 10 , 800 
208 101.7 10,000 
209 101. 9 11,500 
210 102 . 0 10 ,750 
211 101.9 11,200 
212 101. 8 10 , 500 
213 101 . 9 10 , 200 
214 101.8 9,000 
215 102 . 0 9 , 700 
216 102 . l 10 , 250 
217 102 . 4 10 , 600 
218 Challenped 102 . 6 11,000 
-
Data from calf 6087 (continued) 
Virus Isolation from 
Days Temperature Leukocytes Titer Nose Rectum Blood Symptoms 
219 101.8 12,000 
220 102 . 0 8 ,ooo 
221 102 . 0 6 , 250 D, A 
222 102.2 7 , 000 D, A 
223 102.0 1,600 D, A 
224 102. 6 7,300 D, A 
225 105. 0 5,900 + D, A 
226 104.8 10,600 D, A 
227 100.4 15,000 + 
228 101.6 8 ,ooo 
229 101.8 8 , 200 
230 101.6 8 ,000 
231 101.4 8,300 
232 101.2 8 , 400 128 
233 101.4 8 , 200 I-' N 
237 101. 2 8 , 600 N 
239 101 . 0 9 , 000 512 
244 101.8 9,200 
246 101.4 9,000 256 
251 101 . 6 10 , 000 
253 101 . 6 9 , 600 2,048 
258 101. 4 9,400 
260 101.6 9 , 200 2 , 048 
D depression 
A anorexia 
Data from calf 6105 Vaccine - Chl 
Virus Isolat i on from 
Dal'.:s Tem12erature Leukocytes Titer Nose Rectum Blood s~;etoms 
1 102. 8 12 , 500 
2 102 . 5 14,500 
3 102 . 2 14 , 600 
4 101 . 6 13, 500 
5 102 . 3 22 , 500 
6 102 . 6 11, 200 
7 102 .7 1 5,100 
8 102.3 12 ,400 
9 102 . 4 12 , 400 
10 102.5 15 , 250 
11 102 . 2 1 5 , 000 
12 102 . 5 17 , 750 
13 102.3 17,400 
14 Vacc inated 102. 5 17 , 000 
1 5 102 .4 11,600 
I-' 
16 101.8 13,500 N 
().) 
17 101.6 13,900 
18 102 . 0 14 , 200 
19 101. 8 14, 500 
20 102 . 2 14 , ooo 
21 102 .1 14,900 4 
22 102.4 13,000 
23 101.9 13,200 
24 1 02 . 4 19 , 200 
25 102 . 5 14 , 200 
26 102. 5 14 ,500 
27 102. 0 13, 200 
28 102 . 4 14,600 8 
3 5 101 .7 15,000 8 
42 2nd Vacci- 102 . 3 14 , 500 8 
nation 
Data from calf 6105 (continued) 
Virus Isolation from 
Da;p Tem~rature Leuk.oc~es Titer Nose Rec tum Blood SymEtorr.s 
49 102 . 0 13,800 1,024 
56 101.8 18 , ooo 4 , 096 
63 101. 4 17 , 300 8 ,192 
70 102.3 18 , ooo 2 , 048 
11 102 . 0 18 , 200 1,024 
84 102 . 5 1 5 , 000 1,024 
91 101. 5 18 , 200 2 , 048 
98 102 .1 12 , 000 2 , 048 
105 101. 5 12 , 500 1,024 
112 101.8 12 , 000 2 , 048 
119 101. 7 14,500 1,024 
126 101 .8 12 ,700 1,024 
133 101. 9 11,800 1,024 
140 101.6 11,200 512 
147 102 . 1 12 , 800 256 ....... 
154 101.9 14 , 200 512 rv -l= 
161 102 .1 1 5 , 000 1,024 
168 102 .1 14,500 512 
175 101.8 15,500 512 
208 102 . 0 1 5 , 200 512 
209 101.9 16 , ooo 256 
210 101 . 8 15 ,100 256 
211 102 . 0 14,800 256 
212 102 .1 14 , ooo 
213 102 . 0 1 6 , ooo 512 
214 101.8 1 5 , 000 
21 5 101.9 13,200 
216 102 . 1 9 , 000 
217 102 . 0 11 , 200 
218 Challen~ed 101 . 4 12 , 300 
Data fr om calf 6105 (continued) 
Virus Isolation from 
Dai'.:s TemEerature Leukocytes Titer Nose Rectum Blood S~Etoms 
219 102 . 2 16 , ooo 256 
220 101.8 11 , 250 
221 1 02 . 0 13 , 500 
222 101 . 0 8 , 400 
223 101. 2 8 , ooo 
224 102 . 4 7, 200 
225 101. 8 5,400 8 ,182 
226 102 . 0 6 ,4 00 
227 101.4 21 , 500 
228 1 01 . 4 11, 250 
229 101.4 11,800 
230 101. 2 12 ,000 
231 101. 4 13,000 
232 101. 2 13,500 65 ,536 
233 101. 0 13,200 ...... 
tV 
237 101.8 12 , 800 tn 
239 101 . 6 12 , 200 65 , 536 
244 101.8 12 , 000 
246 102 . 0 13 , 000 131,072 
251 102 . 0 12 , 700 
253 101.4 12 , 500 524 ,288 
258 101.2 12 , 200 
260 101.6 12 , 000 1,o48 , 576 
Data from calf 6102 Vaccine - Chl 
Virus Isolation from 
Da_ys Temperature Leukocytes Titer Nose Rectum Blood Symptoms 
1 101. 8 14 , 900 
2 101. 8 1 2 , 000 
3 102 . 4 10 ,800 
4 102 . 4 11 , 600 
5 102 . 3 11 , 900 
6 101.8 11 , 500 
7 102 . 0 13 , 000 
8 102 . 4 14 , 200 
9 102 . 0 15,750 
10 102 . 2 14 , 500 
11 102 . 3 1 5 , 500 
12 101.8 14,900 
13 102 . 2 13,200 
14 Vaccinat ed 102 . 6 16 , 200 
1 5 1 02 . 3 12 , 800 ...... !\) 
1 6 1 02 . 2 1 2 , 900 (JI 
17 101.8 1 2 , 4oo 
18 1 02 . 2 1 2 , 400 
19 101.8 11,400 
20 102 . 0 12 , 200 
21 102 . 4 1 2 ,300 4 
22 102 . 3 15 , 000 
23 102 . 2 14 , 700 
24 101 . 9 14 , 300 
25 101 . 9 14,500 
26 101. 9 12 , 700 
27 101.9 11,000 
28 101 . 6 14 , ooo 8 
35 102 .1 1 5 , 500 8 
42 2nd Vacci - 102 . 1 12 , 900 8 
nation 
,..... 
Dnta from calf 6102 (continued) 
Virus Isolat i on from 
Days Temnerature 
* 
Leukocytes Titer Nose Rectum Blood Symptoms 
49 101.8 18 ,100 384 
56 101.6 17 , 000 1,024 
63 102 . 0 1 5 , 000 2 , 048 
70 101 . 4 16 , 200 1,024 
77 101.8 20 , 000 512 
84 102 . 0 21,000 512 
91 101.6 14,800 512 
98 101. 4 17 , 500 256 
105 101. 6 14,500 256 
112 101 . 5 16 , 500 384 
119 101 . 4 17,000 512 
126 101 . 8 14,900 512 
133 101 . 8 1 5 , 200 512 
140 101. 6 16 , 200 256 
147 101. 5 15 , 800 64 I-' 
IV 
1 54 1 01. 8 15 , 200 128 -...J 
161 101. 4 14,800 128 
168 101. 6 16 ,100 128 
175 101.6 15 , 800 128 
208 101. 8 16 , 900 128 
209 101.8 18 , ooo 1 28 
210 101. 8 14,800 128 
211 101. 7 18 ,100 256 
212 101. 6 17 , 200 256 
213 101 . 8 16 ,1~00 
214 101.7 12 , 800 
215 101. 8 12 , 000 
216 101.7 11 , 000 
217 101.8 12 , 200 
218 Challen9;ed 101. 8 13 , 000 
Data from calf 6102 (continued) 
Virus Isolation from 
Dals TemEerature Leukocytes Titer Nose Rectum Blood s~Etoms 
219 102. 0 18 ,ooo 128 
220 101.8 13,000 
221 101. 8 13,7 50 
222 103 . 0 7, 000 
223 101.2 8 , 800 
224 101.4 10 , 500 
225 102 . 0 7 , 800 2 , 048 
226 107 . 0 7 , 000 D 
2?7 100. 4 18 , 600 
228 102 . 0 13 , 000 
229 101. 8 13 , 200 
230 101. 6 13 , 500 
231 101. 6 13,100 
232 101. 8 12 , 500 131,072 
233 101. 4 12 , 800 ....... 
237 101. 4 13,200 "" CP 
239 102 . 0 13 , 500 131,072 
244 101. 2 13, 200 
246 101. 2 13, 000 16 ,384 
251 101. 2 12 , 700 
253 101. 2 12 , 900 524,288 
258 101. 6 13,200 
260 101. 2 12 , 800 131,072 
D depression 
Data from calf 6116 Vaccine - SA 
Virus I solation from 
Days Temrerature . Leukocytes Titer Nose Rectum Blood Symptoms 
1 102 . 4 12 , 400 
2 102 .1 11 , 000 
3 102 . 0 24 , ooo 
4 101. 7 12 , 200 
5 102 . 3 19 ,750 
6 102 . 7 12 , 400 
7 102 . 3 12 , 000 
8 102 . 5 13 , 200 
9 102 . 3 10,000 
10 102 . 3 12 ,500 
11 101 . 3 1 5 , 000 
12 102 . 5 14 , 500 
13 102 . 5 11,100 
14 Vaccinated 102. 9 13 , 000 
15 102. 4 11 , 600 I-' 
16 102 . 6 12 , 500 "' ID 
17 102 . 6 10 , 200 
18 102 , 4 9 , 400 
19 102 . 5 10 , 500 
20 102 . 4 9 , 800 
21 102 . 4 9 , 800 
22 102.8 8 , 700 
23 102 . 6 9 , 000 
24 103 . 0 11,500 
25 102 . 3 12 , 800 
26 102 . 6 11 , 800 
27 102 . 5 11,600 
28 102 . 4 12 , 000 2 
35 102 . 4 12 , 700 8 
42 101.6 12 , 500 8 
-
Data f r om calf 6116 (continued ) 
Virus I solation f r om 
Days Temperature Leukocytes Titer Nose Rectum Blood Symptoms 
49 101.6 12 , 500 1 , 024 
56 101. 9 13 , 500 8 ,192 
63 101.8 18 , 500 16 , 384 
10 1 02 . 4 16 , ooo 4 , 096 
77 102 . 4 18 ,300 2 , 048 
84 102 . 0 16 , 500 2 , 048 
91 101 .8 13 , 200 2 , 048 
98 101 . 6 11 , 600 2 , 048 
105 101.1 12 , 500 2 , 048 
112 102 . 5 13 , 300 2 , 048 
119 101.6 15 , 500 4 , 096 
126 102 . 0 9 , 800 4 , 096 
133 102 . 0 13 , 650 2 , 048 
140 101.8 16 , 500 2 , 048 
147 101 . 6 12 , 800 1,024 ...... 
154 1 02 . 0 13 , 400 1 , 024 w 0 
161 102 . 0 14 , 400 1,536 
168 101. 6 13 , 200 1,024 
175 101 . 8 12 , 800 1,024 
208 102 . 2 11,800 1 , 024 
209 102 . 0 12 , 600 512 
210 101.8 13 , 200 1,024 
211 101, 6 14 , 600 512 
212 102.0 15 , 200 512 
213 102 . 2 1 5 , 800 
214 102 . 0 16 , 500 
21 5 1 02 , 4 14,ooo 
216 103 . 4 11 , 500 
217 101. 2 13 , 000 
218 Challenped 102 . 0 12 , 200 
Data from calf 6116 {continued) 
Virus Isolation from 
Days Temperature Leukocytes Titer Nose Rectum Blood Symptoms 
219 101. 6 9,800 l,024 
220 102 . 0 11,000 
221 101. 2 12 ,000 
222 102 . 2 11,000 
223 101.4 7,000 
224 101.4 8 , 800 
225 101.8 8 , 250 32 ,768 
226 102 . 2 9 , 750 
227 102 . 0 12 ,750 
228 101.6 14,800 
229 101.6 12 , 900 
230 101.2 12,400 
231 101.2 10 , 800 
232 101.2 11,000 131,072 
233 101.4 11,600 ..... w 
237 101.4 11,500 ..... 
239 101. 4 12 , 000 131 ,072 
244 102. 2 12 , 600 
246 102 . 2 12 , 800 32, 768 
251 103.2 13 , 200 
253 102.2 12 , 500 524 , 288 
258 102 . 4 12 , 000 
260 101.4 ll,800 l,048 , 576 
Data from calf 6071 
Days Temperature 
1 
2 
3 
4 
5 
6 
1 
8 
9 
10 
11 
12 
13 
14 Vaccinated 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
35 
42 2nd Vacci-
nation 
102. l 
101.6 
102 . 3 
102 . 3 
102 . 5 
102 . 6 
102 . 4 
102 . 0 
102 . 6 
102 . 1 
102 . 2 
102 . 4 
102 . 0 
102 . 8 
102 . 7 
102 . 5 
102 . 7 
102 . 6 
102 . 5 
102 . 4 
102 . 5 
102 . 9 
102 . 4 
102 . 6 
102 . 4 
102 . 2 
102 . 4 
102 . 1 
102 . 0 
102 . 6 
Vaccine - None, Contact Control 
Leukocytes 
12 , 600 
13 , 000 
12 , 000 
12 , 900 
24 , ooo 
19 , 100 
13 ,750 
14 , 500 
1 5 , 500 
16 , 800 
16 , 500 
17 , 400 
1 5 , 500 
16 , ooo 
1 5 , 000 
14 ,700 
13, 500 
12 , 000 
9 , 900 
10 , 900 
11 , 000 
12 , 500 
11,600 
10 , 500 
1 5 , 500 
13,200 
12 , 600 
14 , ooo 
14 , 750 
12 ,7 50 
Virus Isolated from 
Titer Nose Rectum Blood Symptoms 
- - ----- - ----111111111 
Data from calf 6071 (continued) 
Virus Isolation from 
Days Temperature Leukocytes Titer Nose Rectum Bl ood Sympt oms 
49 102 . 1 14 , 800 
56 101.8 19 ,700 
63 102 . 0 17 , 600 
70 102 . 0 18 , 250 
77 102 . 3 16 , 500 
84 102 . 5 16 , 500 
91 102 . 1 17, 500 
98 102. 2 16 ,4 00 
105 102 .1 13 , 200 
112 102 . 4 11,400 
119 1 02 . 2 12 , 400 
126 102 . 0 13,200 
133 102 . 1 12 , 750 
140 102 . 0 11,400 
147 102 .4 16 , ooo t--' 
154 14,600 
VJ 
102 . 1 VJ 
161 102 . 0 1 5 , 800 
168 102 . 3 17 ,100 
175 101. 9 18 , 250 
208 102. 0 15,000 
209 102 . 3 17,200 
210 102.1 15,900 
211 102 . 0 14,800 
212 102 . 2 12 , 750 
213 102 . 0 11,500 
214 101.8 10 , 450 
215 101 . 9 11,700 
216 101. 5 12 ,100 
217 1 01. 4 11 , 200 
218 Challenged 101.5 12 , 000 
Data from cal r 6071 (continued) 
Virus Isolation from 
Days Temperature Leukocytes Titer Nose Rectum Blood Symptoms 
219 101.4 20 , 000 
220 101.6 12,800 
221 103 . 0 6 , 250 D 
222 102 . 4 8 , 200 + D 
223 102 . 6 7,700 D, A 
224 101.8 9 ,100 
225 102 . 0 8 , ooo 
226 102.0 12 , 500 
227 101.0 16 , 250 + 
228 101. 6 11,000 
229 101.4 11,300 
230 101 . 4 11,400 
231 101. 4 11,600 
232 101. 4 11,800 256 
233 101.8 12 ,200 t--' w 
237 101.4 12,500 .f= 
239 101.4 12 , 300 512 
244 101.4 12 , 000 
246 101.6 12, 500 2 , 048 
251 101.0 12,800 
253 101.8 13,000 8,192 
258 100.8 12 , 600 
260 101. 0 12 , 900 16 , 384 
D depression 
A anorexia 
Data from calf 6098 
Days Temperature 
l 102 . 0 
2 102.0 
3 io4. o 
4 103 . 4 
5 102 . 0 
6 101. 9 
7 101. 2 
8 102 . 3 
9 101. 4 
10 102.l 
11 102. 4 
12 101. 8 
13 102. 9 
14 Vaccinated 102 . 4 
15 102 . 0 
16 102 . 2 
17 102.3 
18 102 . 4 
19 102. 0 
20 102.8 
21 102.4 
22 102. 5 
23 102 . 5 
24 102 . 8 
25 102. 2 
26 102 . 3 
27 101 . 8 
28 102.l 
35 102.l 
42 2nd Vacci - 102.3 
nation 
Vaccine - Chl 
Leukocytes 
18 , 500 
1 5 ,900 
11, 500 
10,400 
23,000 
17,600 
22 ,000 
24,ooo 
17,400 
16 , 500 
18,500 
17,500 
22 , 900 
15,400 
10,500 
11,500 
12 , 000 
12 ,500 
13,300 
12 , 800 
12 , 500 
13,500 
13,200 
12 , 500 
14,ooo 
12,000 
12 , 500 
14,600 
16 , 900 
12 , 400 
Titer 
-
Virus Isolation from 
Nose Rectum Blood Symptoms 
Data from calf 6098 (continued) 
Virus Isolation from 
Days Temperature Leukocytes Titer Nose Rectum Blood Symptoms 
49 102 . 0 17,000 32 
56 102 .1 17,800 512 
63 102 . 4 16 ,7 50 1,024 
70 101. 9 15,100 512 
77 102. 8 21,500 1,024 
84 102.0 15,000 512 
91 101.8 11,250 512 
98 101. 5 14,500 256 
105 101.4 15 ,500 256 
112 101.8 1 5 ,100 128 
119 102 . 2 14,700 512 
126 102.5 14,200 256 
133 102 . 0 15 ,500 256 
140 102.4 17,400 128 
147 101.9 16,800 256 .._. 
w 1 54 102 . 2 16 ,400 128 O'l 
161 102 . 3 15 ,500 128 
168 102 . 0 16,ooo 128 
175 102 . 4 1 5 ,100 128 
208 102 . 2 16 , ooo 128 
209 102 .1 16 , 500 64 
210 102 . 2 15,000 128 
211 102 . 4 17 , 800 128 
212 102 . 7 18 , 200 128 
213 102 . 2 20 ,750 
214 102.1 15,800 
215 102 . 4 14,600 
216 103 . 3 12 , 500 
217 101. 6 11 , 700 
218 Challenged 101. 0 12,200 
De.ta from calf 6098 (cont inued) 
Virus Isolation from 
Days Temperature 
c 
Leukocytes Titer Nose Rectum Blood Symptoms 
219 1 01 . 2 16 , 500 256 
220 101.8 12 ,750 
221 101.6 17 , 000 
222 101.8 9 , 000 
223 101. 4 9,400 
224 102.4 12 , 400 
225 101. 8 9,250 2,048 
226 104. o 15 ,900 
227 101. 2 18 , 250 
228 102 . 2 17,500 
229 101 . 8 15 , 200 
230 101. 0 14,500 
231 101. 0 12 , 500 
232 101. 6 13, 000 131,072 ...... 
233 100 . 4 14 , 200 w 
-.J 
237 101. 0 14,800 
239 101. 2 1 5 , 200 131,072 
244 101.6 16 , ooo 
246 101. 2 15 , 800 131,072 
251 101. 0 15,200 
253 101.0 14,200 131,072 
258 101.6 14,800 
260 101. 2 14, 500 262,144 
Data from calf 6099 Vaccine - Chl 
Virus Isolation from 
Days TemEerature Leukocytes Titer Nose Rectum Blood s~Etoms 
1 101.4 20 ,600 
2 1 02 . 8 16,200 
3 104 . 5 19 , 000 
4 102 . 2 12 , 900 
5 102 . 9 24,ooo 
6 102. 0 17,100 
7 102 . 5 22 , 500 
8 102 . 4 24 , ooo 
9 102.0 16 , 200 
10 101.5 15,800 
11 102 .7 18,ooo 
12 103. 6 24 ,ooo 
13 102.4 12 , 900 
14 Vaccinated 102 . 2 16 , ooo I-
15 102 . 3 14,250 
w 
CD 
16 102 . 2 13,000 
17 102 . 3 14, 200 
18 102 . 4 13,250 
19 102. 2 14,200 
20 102 . 5 13,800 
21 102.7 13,500 
22 102 . 8 11,900 
23 102 . 4 13,400 
24 102 . 0 12 ,400 
25 102 . 8 12 , 500 
26 102 . 6 14 , ooo 
27 102 . 2 15 , 200 
28 101. 5 14,500 
35 102 . 7 17,500 
42 2nd Vacc i- 102 . 9 16 , ooo 
nation 
Data from calf 6099 (continued) 
Virus Isolation from 
Da;t:s TemEerature Leukocytes Titer Nose Rectum Blood S~Etoms 
49 102 . l 13,800 32 
56 102 . 0 17,300 512 
63 102 . 0 14 , 400 512 
70 101. 9 16 , ooo 256 
77 102 . 4 14,300 256 
84 102 . 4 14,500 128 
91 102 . 0 16 , ooo 256 
98 101. 5 12 , 800 256 
105 102 . 0 12 , 200 ] 28 
112 101. 5 14, 500 64 
119 102 . 0 16 , 500 25h 
126 101.8 1 5 , 500 128 
133 101. 7 13,200 
140 101.9 14 , 600 
147 101.8 14 , 600 32 t-' 
154 
w 
102 . 0 1 5 , 200 lD 
161 102 .1 14 , 500 64 
168 101 . 8 13,200 
175 101. 7 13,600 
208 102 . 0 14,200 
209 102 . 0 15,000 128 
210 102 . 1 14,400 32 
211 102 . 3 14,100 32 
212 102 . 2 13,600 32 
213 101.8 13 , 000 
214 101.6 12 ,000 
215 101. 5 11, 500 
216 102 . 4 10 t 7 50 
217 101.1 11,400 
218 Challenped 101 . 4 12 , 000 
Data f r om calf 6099 (continued) 
Virus I solation from 
Days . Temperature Leukocytes Titer Nose Rectum Blood Symptoms 
219 101.8 16 , 500 16 
220 102 . 0 1 0 , 800 
221 101.l 10 , 250 
222 101.8 7, 400 
223 101. 4 9 , 400 
224 101. 4 8 , 300 
225 101. 4 7 , 500 2 , 048 
226 102 . 0 12 , 750 
227 100 . 0 12 , 750 
228 101. 4 13,500 
229 101.8 13 , 300 
230 101.6 12 , 200 
231 101 . 2 10 ,800 
232 101.8 11 , 700 131 , 072 
233 1 00 . 4 12 , 200 I-' 
237 101 . 4 12 , 800 .+: 0 
239 101 . 5 13 , 400 32 ,768 
244 101.2 12 , 900 
246 101.2 12 , 500 8 ,192 
251 101. 5 12 , 300 
253 101.4 12 , 750 524 , 288 
258 100 . 8 13 , 200 
260 101.0 12 , 500 131 , 072 
Data from calf 6066 Vaccine - None, Contact Control 
Virus I sol ation from 
Days Temperature Leukocytes Titer Nose Rec t um Blood Symptoms 
1 102 . 8 16 , 700 
2 102 . 4 13 , 900 
3 102 . 8 11 , 500 
4 102 . 3 1 5, 500 
5 102 . 0 24,500 
6 102 . 3 16 , ooo 
7 102 . 0 23 , 000 
8 102 . 4 17 , 500 
9 102 . 2 14 , 500 
10 102 . 3 13 , 500 
11 1 01. 7 14, 500 
12 102 . 8 16 , 200 
13 102 . 2 18 , 500 
14 Vaccinated 102. 6 17 , 500 
15 101 . 8 11 , 000 
16 101. 9 12 , 400 
17 101.8 11 , 800 
18 102 . 0 11 , 000 
19 102 . 7 14 , 500 
20 102 . 6 13,100 
21 102 . 5 12 , 600 
22 102 . 4 9 , 600 
23 102 . 2 10, 500 
24 102 . 0 10 , 000 
25 102 . 8 11,000 
26 102 . 0 12 , 200 
27 101.8 21 , 000 
28 102 . 6 11 ,400 
35 102 . 3 14 , ooo 
42 2nd Vacci- 102 . 0 12 , 000 
na tion 
-
Data from calf 6066 (continued ) 
Virus Isolation from 
D9s Temperature Leukocytes Titer Nose Rectum Blood Symptoms 
49 102 . 0 18 , 500 
56 101.8 16 ,100 
63 101. 9 16 , 800 
70 102 . l 16 , ooo 
77 101.9 15 , 500 
84 101. 7 12 , 800 
91 101.8 12 , 200 
98 102 . 0 12 ,100 
105 102 . 1 11,200 
112 101.9 12 , 800 
119 101.7 14,100 
126 101. 8 1 5 , 400 
133 101.6 16 , 200 
140 101 . 5 15,100 
147 101. 6 14 , 900 
1 54 101 . 9 14 , 100 
161 102. 0 14,400 
168 101. 6 13,800 
175 101.8 13,500 
208 101.6 16 , 500 
209 101 . 5 15 , 250 
210 101.4 14,400 
211 101 . 7 13,900 
212 101.8 13 ,100 
213 102 . 0 12 , 000 
214 102. 2 12 , 250 
215 102 . 0 12 , 000 
216 101.6 12 , 800 
217 101.6 12 , 400 
218 Challenp;ed 101. 5 13,000 
... -
Data from calf 6066 (continued) 
Virus Isol at i on f r om 
Days Temperature Leukocytes Titer Nose Rectum Blood Symptoms 
219 101.6 15 , 250 
220 102 . 4 9 , 750 + 
221 102 . 0 8 ,100 
222 101.8 4 , 500 
223 101.6 6 , 500 
224 102 . 4 8 , 500 
225 102 . 0 6 , ooo + D, A 
226 105. 0 12 ,750 
227 101. 4 10 , 800 
228 103 . 8 10 ,100 D 
229 102 . 2 9 , 800 
230 101 . 0 9 , 500 
231 102 . 0 10 , 200 
232 102 . 0 1 0 , 600 128 + 
233 101.8 10 , 800 ...... 
237 101. 4 11 , 400 += VJ 
239 101. 2 11 ,800 512 
244 101. 2 12 , 200 
246 101. 4 11 , 800 512 
251 101.8 11 , 900 
253 101. 2 11 , 500 2 , 048 
258 101.6 11 , 200 
260 101.2 10 ,700 4 , 096 
D depression 
A anor ex ia 
-
Data from calf 6123 Vaccine - SA 
Vir us Isolation from 
Da:z:s 'f'emEerat ure Leukocytes Titer Nose Rectum Blood Sl!!!Etoms 
1 102 , 6 22 , 000 
2 102 . 6 15 , 400 
3 102 . 2 24 , ooo 
4 101.6 15 , 000 
5 104 , 7 21,000 
6 104 . 8 14,ooo 
7 102 . 9 18 , ooo 
8 101.8 22 , 600 
9 102 . 5 16 , ooo 
10 102 . 0 14 , 800 
11 102 . 7 14 , 800 
12 102 . 5 15 , 000 
13 102 , 2 14 , 500 
14 Vaccinated 102 . 4 18 , 900 ...... ~ 
1 5 102 , 0 10 , 700 
~ 
16 102 . 2 11 , 200 
17 102 . 5 10 , 000 
18 102 . 5 11 , 300 
19 102 . 2 11 , 200 
20 102 . 6 10 ,800 
21 102 , 4 10 , 000 4 
22 102 . 9 9 , 500 
23 102 . 6 10 , 200 
24 103 . 4 9 , 000 
25 102 . 7 9 , 000 
26 102 . 4 10 , 500 
27 102 .1 10 , 200 
28 102 . 3 10 , 200 4 
35 101. 5 11 , 900 4 
42 2nd vacci - 102 . 5 13 ,100 32 
nation 
-
Data from calf 6123 (continued) 
Virus I solati on from 
Daxs Temper ature Leukocytes Titer Nose Rectum Bl ood Symptoms 
49 102 . 2 10,700 2 ,048 
56 102 . 4 12 ,500 16 ,384 
63 102 . 3 12 , 000 16 ,384 
70 102 . 6 13,000 4, 096 
77 102.3 9,800 8 ,192 
84 102 . 4 14 , 200 4, 096 
91 102. 6 13,000 4,096 
98 102.l 12 ,300 4,096 
105 102 . 5 16 , ooo 4,096 
112 102 . 4 1 2 , 800 2 , 048 
119 102 . 2 11,800 4 , 096 
126 102 . 6 13 , 000 4,096 
133 101 , 8 i 4 , 8oo 4 , 096 
140 102 . 2 1 5, 200 2 , 048 
147 102 . 5 13 , 800 1,024 f-' + 
154 101.9 11,800 1,024 (Jl 
161 101. 8 1 0 , 900 1,024 
168 102 . 0 12 , 200 1,024 
175 102 . 2 13,400 l,024 
208 102 . 2 14 , 800 1,024 
209 102 . 5 i 6 , ooo 1,024 
210 102 . 0 i 4 , 8oo 1,024 
211 101, 9 1 5 ,300 512 
212 102. 0 17,800 512 
213 101.8 16 ,ooo 
214 101. 6 15,200 
215 101.8 12 , 800 
216 101.7 11,500 
217 101. 9 12 , 600 
218 Challenged 
Data from calf 6123 (continued) 
Days Virus Isolation from 
Postchallenlle TemEerature Leukocytes Titer Nose Rectum Blood SymEtoms 
219 102 . 0 14,750 1,024 
220 102 . 2 13,250 
221 101.9 1 2 , 500 
222 102 .4 13, 500 
223 103 . 0 7 , 500 
224 102 . 0 8 ,700 
225 102 .4 9 , 250 2 , 048 
226 101 . 6 8,650 
227 101.2 18 , 250 
228 101.6 17 , 500 
229 101 .8 1 5 , 200 
230 101.8 14,500 
231 101.4 12,500 
232 101.8 13,200 131,072 
233 101.8 13,500 ..... ~ 
237 102 . 0 14 , 200 O'l 
239 102 .0 14,600 131,072 
244 102 . 0 14,300 
246 101.4 13,800 32 , 768 
251 101.6 13,500 
253 101.4 13,800 262 ,144 
258 100 . 8 14 , 200 
260 101.6 13,900 524 , 288 
Data from calf 6119 Vaccine - SA 
Virus Isolation from 
Days Temperature Leukocytes Titer Nose Rectum Blood Symptoms 
1 102 . 0 13 ,100 
2 101.0 14 , 400 
3 102 .7 17 , 700 D, R 
4 101.6 11,400 D, R 
5 103. 5 23,400 D, R 
6 101.8 17, 500 
7 102 . 3 1 5 , 000 
8 101.7 11,900 
9 102 . 6 17,000 
10 102 . 0 1 2 , 000 
11 1 02 . 4 22 , 000 
12 102 . 3 18 , 500 
13 102 . 6 11 , 000 D 
14 Vaccinated 101 . 8 12,500 
15 102 . 6 12 , 500 I-' 
16 102 . 5 12 , 800 .::--..J 
17 102 . 4 11,250 
18 102 . 8 14 , 900 D 
19 102 . 4 13,200 
20 102 . 6 14,ooo 
21 102 . 3 15,500 4 
22 103 . 4 13,500 D 
23 102 . 4 12 , 800 
24 102 . 8 10 , 400 D 
25 102.4 9 , 200 
26 102.6 11,400 
27 102 . 5 14 , 200 
28 102.4 20 , 200 8 
35 102 . 2 1 4 , ooo 8 
42 2nd Vacci - 102 .3 13,100 32 
nation 
Data from calf 6119 (continued) 
Virus Isolation from 
Dals Tem;eer ature Leukocytes Titer Nose Rectum Blood S;r!!!Etoms 
49 101.4 11,300 8 ,192 
56 101.6 14 , ooo 8 ,192 
63 103 . 3 16 , 350 16 , 384 D 
70 102 . 4 15 , 000 16 , 384 
77 102 . 0 14 , ooo 16 , 384 
84 102 . 4 16 , 200 8 ,192 
91 101.8 14, 500 8 ,192 
98 102 . 6 16 , 500 8 ,192 D 
105 102 .4 18 , ooo 8 ,192 
112 102 . 2 13 , 500 8 ,192 
119 101.8 12 , 500 4 , 096 
126 101.8 13 , 500 4 , 096 
133 102 . 0 14 , 200 4 , 096 
140 102 . 4 15,100 2,048 
147 101.8 14 , 600 1 , 024 ....... 
154 102 . 2 15, 400 2 , 048 ~ CXl 
161 102 . 0 14 , 600 2 , 048 
168 101.8 13,600 2 , 048 
175 102 . 2 14 , 700 2 , 048 
208 102 . 4 15 , 200 2 , 048 
209 102 . 4 15 ' 700 2 , 048 
210 101. 5 14 ,800 2 , 048 
211 101.8 17,500 1,024 
212 101.6 15 , 400 512 
213 101.8 14,800 
214 101.7 13,600 
215 102 . 0 14,300 
216 102 .l 13 , 000 
217 101.6 14,200 
218 Challenged 101.9 12 , 800 
Data from calf 6119 (continued) 
Virus Isolation from 
Days Temnera.ture Leukocytes Titer Nose Rectum Blood Symptoms • 
219 101. 8 1 5,7 50 2 , 048 D,A, R cough , dep . 
anorexia. 
220 102 . 2 11,500 D,A, R 
221 101. 6 12 ,000 D,A,R 
222 102 . 8 12 , 000 D,A, R 
223 103. 2 6 , 400 D,A,R 
224 102 . 6 10 , 400 D,A ,R 
225 101. 6 1 0 , 000 4,096 D, A, R 
226 106 . o 8,750 D,A, R 
227 102. 4 11,750 D, A,R 
228 )..01. 6 12 ,750 D, A, R 
229 101.4 12 , 500 D, A, R 
230 102 . 0 12 ,000 D,A, R 
231 101.4 11,500 D 
232 102. 0 12 ,000 131,072 D I-' +:" 
233 101.8 12 , 400 D lD 
237 101.4 12 ,200 D 
239 102 . 0 11,800 131,072 D 
244 101.4 11,400 D 
24 6 101 , 2 10 , 800 32 ,768 D 
251 102 , 0 10,400 D 
253 101. 8 11,000 131,144 D 
258 101. 6 11 , 400 D 
260 101. 2 12 , 000 522 , 288 D 
D depression 
A anorexi a 
R r espiratory (cough) 
.. 
Data from calf 6121 Vaccine - None , Contact Control 
Virus I solation from 
Days Temperature Leukocytes Titer Nose Rectum Blood Symptoms 
l 101.8 19 ,800 
2 102 .4 1 5 ,400 
3 102.4 15,000 
4 101.3 16 , 300 
5 102.4 24 , ooo 
6 102.2 19 ,100 
7 102.5 24,ooo 
8 101. 7 21,000 
9 102. 0 13 , 500 
10 101.8 14 ,100 
11 101 . 9 14,ooo 
12 102.l 11,200 
13 102 . 4 17,100 
14 Vacc inated 102. 2 14,750 t-' 
15 101.9 11,500 tn 0 
16 101. 8 12 , 600 
17 102 . 2 11,900 
18 101. 8 12,500 
19 102.4 12 , 800 
20 102 . 2 12 .100 
21 102.l 12 , 700 
22 102 . 7 10,500 
23 102 .1 11,000 
24 103 . 4 10,250 
25 102 . 3 11,250 
26 102 . 4 10 , 400 
27 103 . 4 9 , 200 
28 102.4 12 , 200 
35 102 . l 12 , 600 
42 2nd Vacci - 102. 2 14,ooo 
nation 
Data from calf 6121 (continued) 
Virus Isolation from 
Dais TemEerature Leukocytes Titer Nose Rectum Blood S~Etoms 
49 102 , 4 13 , 300 
56 102 . 6 15 ,100 
63 102.6 16 , 800 
70 103 . l 1 5 , 200 
77 102 , 4 18 , 500 
84 101. 6 12 ,750 
91 102 . 5 13 , 500 
98 102 . 2 12 , 750 
105 1 02.1 13 ,100 
112 101.9 12 , 250 
119 101 . 8 13 , 300 
126 101 . 6 14 , ooo 
133 101.7 14 , 200 
140 101 . 8 1 5 ,200 
147 1 01 . 5 16 ,700 I-' 
154 101 . 5 1 5 , 000 <.n I-' 
161 101.7 14,800 
168 101.8 13 , 900 
175 101.6 13 ,700 
208 101.8 20,000 
209 101.6 18 , 700 
210 101 . 5 17 ,100 
211 101.9 15 , 200 
212 102 . 0 13 ,100 
213 102 . 6 12 , 400 
214 102 . 8 10 , 500 
215 101. 6 11 , 700 
216 101 . 5 12 , 600 
217 1 01 . 6 12 , 900 
218 Challenp:ed 101. 5 12 , 000 
Data from calf 6121 (continued) 
Virus Isolation from 
Days Temperature Leukocytes Titer Nose Rectum Blood Symptoms 
219 101.4 15,000 
220 102.0 12 , 500 
221 101.4 8 ,400 D, A 
222 102.2 10 , 200 
223 102 . 4 9,800 D,A,R 
224 101. 0 10,300 
225 101.4 10,000 + 
226 104.o 16,500 D, A 
227 101.8 1 5 , 600 
228 102 . 2 14,500 
229 101. 6 14,ooo 
230 101. 0 13,400 
231 101. 2 14,750 
232 101. 8 14,500 64 
233 102 . 4 14,200 t-' 
237 101.2 1 5,000 Ul rv 
239 101. 2 15,400 128 
244 101.4 15,200 
246 101. 2 14,800 512 
251 100.0 14,200 
253 101.4 14,500 2 , 048 
258 101.4 14,700 
260 101. 0 14,400 1,024 
D depression 
A anorexia 
R respiratory (cough) 
Data from calf 6086 Vaccine - SA 
Virus Isolation from 
Days Temperature Leukocytes Titer Nose Rectum Blood Symptoms 
1 101 . 7 13,500 
2 101. 0 8 , 000 
3 102 . 2 9 ,000 
4 101.8 10,300 
5 102 , 2 12 ,400 
6 102. 5 18 , ooo 
1 101.4 12 ,400 
8 102 , 6 10,000 
9 102 ,4 19 , 800 
10 101.8 12,000 
11 101.5 12,400 
12 102 . 4 12,600 
13 102,2 12,600 
14 Vaccinated 102.0 11,800 
15 102 , 2 11,200 I-' 
16 102 . 0 10 , 200 <.n (.;.) 
17 102,l 9 , 600 
18 101. 6 9 , 600 
19 101.8 9 , 300 
20 102. 2 9 , 000 
21 102,2 9,000 4 
22 102, 4 8 , 500 
23 102.l 10,300 
24 102. 2 10,000 
25 102.0 13,400 
26 102 .4 12 ,700 
27 102. 2 12 ,400 
28 102 .3 11,900 8 
35 101. 8 11,300 8 
42 2nd Vacci - 102 . 2 11,200 32 
nation 
Data from calf 6086 (cont inued) 
Virus Isolation from 
Days Temperature Leukocytes Titer Nose Rectum Blood Symptoms 
49 101.7 9 ,400 8 ,192 
56 101 . 7 15 , 500 16 , 384 
63 101 . 6 19 ,100 16 , 384 
70 101.8 13 , 300 16 , 384 
77 101.6 12 , 500 16 , 384 
84 101 .8 12 , 500 8 ,192 
91 101.8 15,900 16 ,384 
98 101.8 8 , 800 16 , 384 
105 101.0 10 , 800 8 , 192 
112 102 .1 9 , 800 16 , 384 
119 102 . 0 11 , 500 16 , 384 
126 101. 8 11,800 16 , 384 
133 102 . 0 13 , 200 8 ,192 
140 102 . 0 12 , 500 4 , 096 
147 102 . 2 12 , 400 2 , 048 f-' 
154 101. 8 11,800 4,096 (Jl + 
161 101 . 6 12 , 000 4,096 
168 102 . 2 10 , 600 2 , 048 
175 102 . 4 10,000 2 , 048 
208 102 . 3 9 , 000 2 , 048 
209 101 . 8 10 , 600 2 , 048 
210 102 . 2 11,500 2 , 048 
211 102 . 2 11,800 2 , 048 
212 102 . 2 12 , 000 2 , 048 
213 102 . 1 11,400 
214 102 . 2 11,800 
21 5 101. 5 11,500 
216 101.8 9 , 800 
217 101 .8 10 , 200 
218 Challenged 101.5 11,000 
-
Data from calf 6086 (continued) 
Virus Isolation from 
Da~s Temperature Leukocytes Titer Nose Rectum Blood s~Etoms 
219 101.8 12 , 000 2,048 
220 101. 6 11,300 
221 101. 2 10 , 500 
222 102. 0 13 , 400 
223 102 . 0 12 , 800 
224 102 . 0 12,700 
225 101.8 12 , 500 2,048 
226 102.0 14,500 
227 102 . 0 18 ,800 
228 101.8 13,000 
229 101.8 13 , 200 
230 101 . 6 13,500 
231 101. 2 13,400 
232 101. 4 13 ,800 4,096 
233 101 . 0 13,200 t-' V1 
237 101. 2 14,ooo c.n 
239 101. 2 13 , 600 4,096 
244 101. 4 13,200 
246 101. 5 12,800 2 , 048 
251 101.6 13,600 
253 101.2 13,200 8,192 
258 101.2 12 ,700 
260 101. 0 11,900 4,096 
l 
Data from calf 6088 
Days Temperature 
1 101. 4 
2 103 . 2 
3 101.9 
4 101 . 4 
5 103 . l 
6 102 . 4 
7 102 . 4 
8 101.3 
9 103 . 0 
10 101 . 5 
11 102 . 7 
12 101.4 
13 101.9 
14 Vaccinated 101.1 
15 102. 2 
16 102 . 0 
17 101.9 
18 102 . 2 
19 102 . 0 
20 101 . 9 
21 101 .8 
22 102 . 4 
23 101. 5 
24 102 . l 
25 102 . 0 
26 101.6 
27 102 . 4 
28 102 . 0 
35 102 . 3 
42 2nd Vacci - 102 . 4 
nation 
Vaccine - None , 
Leukocytes 
20 , 000 
9 , 400 
16 , ooo 
11 , 000 
23 , 000 
17 , 200 
9 , 250 
7,100 
8 , 500 
11,750 
10,500 
13,000 
10 ,100 
13 , 600 
1 0 , 000 
10,400 
9 , 600 
9 , 800 
12 , 750 
10 , 700 
9 , 000 
8 , ooo 
9 ,100 
8 , 500 
8 , ooo 
8 , 200 
9 ,100 
9 , 500 
12 ,750 
8 ,700 
-
Contact Control 
Virus Isolation from 
Titer Nose Rectum Blood Symptoms 
....... 
lJl 
CJ) 
Data from calf 6088 (continued ) 
Virus Isolation from 
Dal:s TemEer ature Leukocytes Titer Nose Rectum Bl ood SymEtoms 
49 101 . 9 9 , 700 
56 102 . 0 12 , 000 
63 101 . 8 11 , 200 
70 102 . 1 10 , 600 
77 101.8 1 0 , 500 
84 102 . 4 10 , 000 
91 102 . 3 12 , 600 
98 102 . 0 11 , 400 
105 102 . 2 10 , 800 
112 102 . 1 10 ,400 
119 102 . 1 10 , 700 
126 101.9 11,000 
133 101. 7 11 ,4 00 
140 102 . 0 10 , 900 
147 101 . 8 12 ,100 ...... 
1 54 101 . 5 12 , 400 (.J1 -.,J 
161 101. 7 1 5 , 000 
168 101 . 6 i 6 , ooo 
175 101.7 15 , 400 
208 101. 5 i 6 , ooo 
209 101 . 6 12 , 750 
210 101. 4 11 , 800 
211 101.6 11 , 250 
212 101.9 10 , 7 50 
213 102 . 0 10 , 200 
214 102 . 2 10,900 
21 5 102 . 7 9 , 600 
216 101 . 0 10 , 200 
217 101 . 5 11 , 000 
218 Challenp;ed 101.0 12 , 100 
Data from calf 6088 (continued) 
Vi rus Isolation from 
r>ars TemEerature Leukoc~es Titer Nose Rectum Blood S:z:.!!!Etoms 
219 101.8 16 , ooo 
220 102 . 0 7 , 250 + 
221 101 . 8 6 , 250 D, A 
222 101. 4 8 , 200 + D, A 
223 102 . 4 9 , 000 D, A 
224 104 . 2 9 , 200 D, R 
225 103 . 0 8 , ooo + L stiff 
226 102 . 4 10 , 200 L stiff 
227 101.8 9 , 250 + 
228 101 . 4 9 , 000 
229 101. 8 9 , 300 
230 101 . 0 9 , 500 
231 101.4 9 , 200 
232 101 . 4 9 , 500 64 + 
233 102 . 4 9 , 300 ~ 
237 101.4 9 , 600 tn 00 
239 101.9 10 , 000 256 
244 102 . 0 11 , 000 
246 102 . 0 10,600 512 
251 101.6 9 , 800 
253 101.6 9 , 600 2 , 048 
258 101.2 9 , 500 
260 101.8 9 , 800 4 , 096 
D depres si on 
A anorexia 
L l amin i tis 
R respiratory ( cou~b) 
Data f r om cal f 6100 Vaccine - BPL 
Virus Isolation from 
Days Temper ature Leukocytes Titer Nose Rec tum Blood Sympt oms 
l 101.8 11,200 
2 101. 2 11,000 
3 101 . 7 10 , 400 
4 101. 2 11,900 
5 103. 0 15 , 200 
6 101 . 6 16 , ooo 
7 102 . 5 14 , 900 
8 102 . 4 12 , 900 
9 102 . 4 11,750 
10 102 . 4 13,200 
11 102 . 3 13 , 500 
12 102 . 4 14 , oco 
13 102 . 6 12 , 700 
14 Vaccinated 102 . 0 14 , 600 
15 102 . 3 12 , 500 I-' 
16 102 . 2 12 , 000 (J1 <.D 
17 102 . 2 11,600 
18 102 . 1 11,800 
19 102 . 4 10 ,100 
20 102 . 3 10 , 300 
21 102 . 6 11,200 
22 102 . 3 11 , 800 
23 102 .1 11,000 
24 102 . 5 12 , 750 
25 101.8 22 , 200 
26 102 . 4 14,200 
27 101 . 8 10 , 200 
28 102 . 2 13,800 
35 102 . 4 12 , 800 8 
42 2nd Vacci- 102 . 3 11 , 000 8 
nat i on 
.. 
Data from calf 6100 (continued) 
Virus Isolation from 
Days Temperature 
c 
Leukocytes Titer Nose Rectum Blood Symptoms 
49 102 . 4 13,800 384 
56 102.0 15 ,000 4,096 
63 102 . 5 17,500 8,192 
70 101 . 7 13,500 4 , 096 
77 102 . 2 8 , ooo 2,048 
84 101. 9 11,250 2 , 048 
91 1 02.3 12,000 2,048 
98 101. 5 11,800 1,024 
105 101.7 10, 600 1,536 
112 101.8 8 , 750 1,536 
119 101. 7 10 , 000 1,024 
126 1 01. 9 11,100 2,048 
133 102.3 11,800 1,024 
140 101.9 12,600 1,024 
147 102 . 2 12 ,800 1,024 f-' 
154 101. 8 11,900 1,024 01 0 
161 101. 9 13,000 1,024 
168 102 . 2 14,200 512 
175 102 . 3 15,000 512 
208 102.1 14,ooo 512 
209 101.8 12,500 256 
210 102 . 3 12,800 256 
211 102 . 3 13, 000 512 
212 102 .1 12,500 1,024 
213 102.0 11,700 
214 102 .1 11,200 
215 102 . 2 10,200 
216 102 . 2 9,000 
217 101.8 10,400 
218 Challenr;ed 102 . 2 11,000 
Data from calf 6100 (continued) 
Virus Isolation from 
Days Temperature Leukocytes Titer Nose Rectum Blood Symptoms 
219 101 . 8 12 , 500 1,024 
220 101.8 8 , 750 
221 101.8 10 , 300 
222 102 . 2 15,000 
223 101.8 10,300 
224 101.8 13,500 
225 103. 0 8 ,500 2 , 048 D 
226 104 . o 7 , 750 D 
227 101. 8 12,250 
228 101. 6 7,500 
229 101.4 10,000 
230 101.8 12,400 
231 101 . 4 12,600 
232 101.4 12 ,400 131,072 
233 101 . 6 11,800 I-' 
237 101. 6 11,200 CJ) I-' 
239 101 . 2 10 , 800 131,072 
244 102.2 12,000 
246 101.2 11 , 800 32 ,768 
251 101.8 12 , 000 
253 101 . 0 11,400 262,144 
258 101. 0 11,800 
260 101. 2 11 , 800 262 ,144 
D depression 
Data from calf 6097 Vaccine - BPL 
Virus Isolat i on from 
Days Temper ature Leukocytes Titer Nose Rec t um Bl ood Symptoms 
1 101.8 17,000 
2 102 . 0 10 , 000 
3 102 . 4 10 ,100 
4 102 . 6 12 , 500 
5 102 . 2 24 , ooo 
6 102 . 0 24 , ooo 
1 102 . 4 16 , 800 
8 101.8 16 , 500 
9 102 .l 12 , 600 
10 101.8 12 , 000 
11 101. 5 14 , ooo 
12 101.8 13 , 000 
13 102 . 2 15 , 000 I-' 
14 Vaccinated 102 . 0 11 , 000 (]\ I\) 
1 5 102 . 5 14 , 500 
16 102 . 4 13 , 600 
17 102 .l 13 , 000 
18 102 . 3 12 , 500 
19 102 . 2 10 ,100 
20 102 . 4 10 , 900 
21 102 . 5 11,600 
22 102 . 0 10 , 000 
23 102 . 9 10 , 500 
24 102 . 5 13 , 000 
25 102 . 6 9 , 800 
26 102 . 4 10 , 500 
27 102 . 5 9 , 800 
28 102 . 4 10, 900 
35 101.8 11,900 
42 2nd Vacci - 102 . 0 10 , 000 2 
nation 
• 
Data from calf 6097 (continued) 
Virus Isolation from 
Days Temper ature Leukocytes Ti ter Nose Rectum Blood Symptoms 
49 101.8 11,700 1 , 024 
56 102 . 0 13 , 600 4 , 096 
63 101 . 5 11 , 000 4 , 096 
70 102 .l 12 , 000 2 , 048 
77 102 . 2 12 , 000 1,024 
84 101.9 11 , 250 2 , 048 
91 101.6 9 , 600 2 , 048 
98 102 .4 9 , 000 1,024 
105 101.7 7, 500 1,024 
112 101. 6 9 , 200 1,536 
119 101.9 9 , 000 2 , 048 
126 101.8 10 , 400 2 , 048 
133 102.0 11,000 1,024 
140 101 . 6 11 , 300 1,024 ....... 
147 101.7 12 , 400 512 °" w 
154 1 01. 5 11 , 900 512 
1 61 101.8 13 , 000 256 
168 101.9 1 5 , 200 256 
175 101. 5 18 ,100 128 
208 101. 5 17 , 900 256 
209 101.6 20 , 000 128 
210 101. 5 13,000 256 
211 102 , 0 11,200 256 
212 102 . 2 7 , 600 256 
213 101. 9 9 , 200 
214 102.1 9 , 600 
21 5 102 .4 8 , 400 
216 102 . 5 1 ,600 
217 101.8 9 , 000 
218 Challenged 101. 6 11,000 
Dat a from calf 6097 (cont inued ) 
Virus Isolation from 
Dals TemEerature Leukocytes Titer Nose Rectum Blood s~Etoms 
219 102 . 0 20 , 000 256 
220 102 . 0 8 , 900 
221 101. 8 6 , 300 
222 102 . 4 8 , 200 
223 102 . 0 5,800 
224 102 . 0 6 , 900 
225 102 . 8 6 , ooo 8 ,192 D, E 
226 107 . 0 10,200 D 
227 101. 2 19,250 
228 101. 4 11,750 
229 101. 6 10,200 
230 101. 4 9,600 
231 101 . 2 9 ,800 
232 101.4 10 , 200 131,072 
233 101. 0 10 , 600 .... 
237 101.4 11,200 0\ .f:"" 
239 101.4 10,800 131,072 
244 101.6 10 , 200 
246 101. 2 9 , 600 131 , 072 
251 101.8 10 ,4 00 
253 101. 2 10 , 400 524 , 288 
258 101.4 10 , 200 
260 101.4 9,800 >l , 048 , 576 
D depression 
E enteritis 
Data from calf 6106 
Days Temperature 
1 102 . 2 
2 101. 8 
3 102 . 8 
4 102 .1 
5 102 . 6 
6 102 , 4 
7 101.9 
8 102 . 4 
9 103 . 4 
10 102 . 4 
11 102 . 0 
1 2 103 . 2 
13 102 . 6 
14 Vaccinated 102 . 5 
15 103.1 
16 102.5 
17 102.6 
18 102.3 
19 103.2 
20 102.8 
21 103 . 2 
22 102 . 6 
23 102 . 6 
24 102 . 5 
25 102.4 
26 102. 9 
27 102 . 0 
28 102 . 9 
35 102. 4 
42 2nd Vacci- 102 . 7 
nat ion 
Vaccine - None , Contact Control 
Leukocytes 
17 , 500 
13 , 000 
11,600 
10,600 
17,000 
24 ,ooo 
14,ooo 
10,700 
10,850 
12,300 
12,250 
11,000 
12,800 
11,800 
7,500 
8,900 
10 ,400 
9 , 000 
8 , 200 
9 , 800 
11,7 50 
10, 750 
10 , 900 
9 , 500 
1 0 , 000 
8,300 
10 ,400 
10 ,7 50 
9 , 000 
8 , 900 
Virus Isolation from 
Titer Nose Rectum Blood Symptoms 
Data from calf 6106 (continued ) 
Virus I solation from 
Da;rs TemEerature Leukocytes Titer Nose Rectum Blood S~Etoms 
49 102 . 8 11 , 60() 
56 102 . 9 12 ' 7 50 
63 102 . 0 10 , 900 
70 102 . 4 10 ,7 50 
77 102 . 6 10 , 000 
84 102 . 5 10 , 000 
91 102 . 4 10 ,700 
98 102 . 0 11,000 
105 101 . 9 9 , 000 
112 102 .1 9 , 900 
119 101. 9 8 , ooo 
126 101.8 8 , 500 
133 102 . 1 9 , 250 
140 101.8 10 , 250 
147 101 . 6 11,000 ...... O'\ 
1 54 102. 0 10 , 500 O'\ 
161 102 . 1 9 , 600 
168 101. 9 9 , 200 
175 101.7 8 , 500 
208 102 . 0 10 , 500 
209 101. 8 8 , ooo 
210 101. 9 11, 500 
211 101.8 10 , 750 
212 102 . 0 9 , 250 
213 102. 2 9 , 000 
214 101. 9 8 , 500 
215 101.8 7 , 750 
216 102 . 0 8 , 200 
217 102.1 10,000 
218 Challenged 102 . 0 9 , 000 
Data from calf 6106 (continued ) 
Virus Isolation from 
Dals TemEerature Leukocytes Titer Nose Rectum Blood SymEtoms 
219 101 . 4 10,500 
220 101.6 7,500 
221 102 . 0 4,500 D 
222 102 . 2 7,400 + D 
223 102 . 8 6 , 200 D 
224 102 . 8 7 , 400 D, E 
225 101.6 7,000 + + + D, E 
226 102 . 0 11,000 
227 102 . 8 1 5 , 500 + 
228 101 . 8 7,000 
229 102 . 2 7 , 600 
230 101.9 8 , 000 
231 1 01.4 8 , 200 
232 101.4 8 , 600 256 
I-' 
233 101. 8 8,900 O'\ 
--J 
237 101. 8 9 ,400 
2~0 
.J; 101. 2 10 , 000 512 
244 101. 5 9 , 800 
246 101. 4 9 , 200 512 
251 101.8 8 , 800 
253 101. 8 9 , 200 8 ,182 
258 101 . 4 8 , 500 
260 101.4 8 , 400 16 , 384 
D depression 
E enteritis 
Data from calf 6104 
Days Temperature 
s 
1 103 . 2 
2 102 . 8 
3 102 . 0 
4 102 . 8 
5 102 . 2 
6 102 . 1 
7 102 . 3 
8 101.7 
9 102.3 
10 102 . 5 
11 101. 6 
12 102 . 3 
13 103 . 0 
14 Vaccinated 101.9 
15 101.9 
16 102 . 0 
17 102.2 
18 102 . 4 
19 102 . 4 
20 102 . 2 
21 102 . 5 
22 103 . 0 
23 102 . 0 
24 102 . 9 
25 102. 5 
26 102. 4 
27 102 . 3 
28 102 . 7 
35 102 . 3 
42 2nd Vacci - 102 . 0 
nation 
Vacc ine - None , Barn Control 
Leukocytes 
10 , 000 
12, 500 
24,ooo 
14 , 300 
24,500 
12,750 
15 , 200 
22,000 
13 , 500 
11, 000 
12 , 500 
1 5 , 000 
21 , 000 
1 5, 300 
13,250 
14,500 
12 , 750 
13 , 750 
13 ,100 
12 ,750 
12 , 500 
13,000 
12 , 500 
13,250 
12 , 500 
12 ,400 
15 , 500 
13 , 800 
12 , 000 
15 , 500 
Titer 
Virus Isolation from 
Nose Rectum Blood Symptoms 
Data from calf 6104 (continued) 
Virus Isolation from 
Dals TemEerature Leukocyte s Titer Nose Rectum Blood S~Etoms 
49 102 . 0 1 5 , 500 
56 101.9 17 , 000 
63 102 . 4 16 , 700 
70 102 . 8 1 5 , .200 
77 102 . 4 14 , ooo 
84 102 . 4 8 , ooo 
91 102 . 5 12 , 000 
98 102 . 0 14 , 500 
105 102 . 2 10 , 800 
112 102 . 1 7 , 800 
119 102 . 2 10 , 000 
126 i o2 . u 12 , 600 
133 102 . 2 14 , 800 
140 102 . 4 16 , ooo 
147 102 . 5 14 , 500 ...... 
154 102 . 0 16 , 200 IJ'\ '.0 
161 102 . 4 15 , 500 
168 102 . 2 16 , ooo 
175 102 . 4 17 , 000 
208 102 . 5 13 , 000 
209 102 . 2 17 , 300 
210 102 . 0 14 , ooo 
211 102 . 0 12 ,750 
212 101.8 14 , 200 
213 101. 9 13,600 
214 102 . 0 12 , 000 
215 101.8 12 , 800 
216 101 . 7 13 , 200 
217 101.6 12 ,7 50 
218 Chall enged 101 . 9 12 , 000 
Data from calf 6104 (continued) 
Virus I solation f r om 
Days Temnerature • Leukocytes Titer Nose Rectum Blood Symptoms 
219 101.8 16 , ooo 
220 102 . 4 11 , 000 + + 
221 101 . 4 13 , 100 D 
222 101. 6 11 , 200 D 
223 102 . 8 7 , 600 D 
224 102 . 8 1 ,600 D 
225 102 . 0 7 , 800 + 
226 102 . 0 17 ' 750 
227 104 . 2 9 , 750 
228 101. 4 15 , 250 
229 101 . 6 14,800 
230 101.4 14 , 500 
231 101. 0 12 , 400 
232 101. 2 14 , ooo 32 + 
233 101. 4 13 , 750 
237 101 . 8 15 , 000 ........ --l 
239 102 . 2 14 , 800 128 0 
244 101 . 8 14 , 500 
246 102 . 0 13 , 700 512 
251 101. 8 14 , 600 
253 101 . 8 14 , 200 2 , 048 
258 101 . 2 13 , 900 
260 101 . 8 14 , 200 4 , 096 
D depression 
• 
Data from calf 6120 
Days Temperature 
1 101.8 
2 102 . 8 
3 102 . 9 
4 102 . 0 
5 102 . 5 
6 101. 9 
7 101.8 
8 102.1 
9 101.8 
10 102.4 
11 102 . 3 
12 102 . 4 
13 102 . 4 
14 Vacc i nated 102 . 0 
1 5 102 . 5 
16 102 . 4 
17 102 .1 
18 102 . 4 
19 102. 5 
20 102 . 4 
21 102 . 4 
22 102 . 7 
23 102 . 5 
24 102 . 8 
25 102.4 
26 102 . 8 
27 102 . 4 
28 102 . 5 
35 102 . 6 
42 2nd Vacc i - 102.3 
nation 
Vaccine - None , Barn Control 
Leukocytes 
19,700 
14,800 
23, 500 
24,ooo 
19 , 800 
14,300 
12 ,4 00 
12 , 250 
14,800 
12 , 800 
15 , 000 
13,250 
12 , 250 
12 , 250 
12 , 500 
12 ,100 
11, 750 
12 ,4 50 
10 , 600 
10 ' 750 
11,700 
11,500 
11,800 
11, 500 
11,300 
11,7 50 
12 , 000 
12 , 250 
11,7 50 
14 , ooo 
Titer 
Virus Isolation from 
Nose Rectum Blood Symptoms 
' 1 
Data from calf 6120 (continued) 
Virus Isolation from 
Days Temperature Leukocytes Titer Nose Rectum Blood Symptoms 
49 102 .1 17,900 
56 102 . 0 1 5 , 000 
63 102 . 5 13,500 
70 101. 8 1 5, 500 
77 102 .1 13 , 000 
84 102 . 2 12 , 500 
91 102 . 0 13 , 200 
98 102. 2 10 , 250 
105 101 . 8 11,600 
112 102.2 12 , 200 
119 102 . 0 11,900 
126 101. 7 10 , 900 
133 102 . 0 12 , 600 
140 102 . 2 11,200 
147 102 .5 12 , 750 
154 102 . 0 11,800 
161 1 01.8 12 , 900 
168 101.9 14, 200 
175 102.4 13,100 
208 102 . 3 16 , ooo 
209 102 . 2 15 , 700 
210 101.8 14,300 
211 102 . 2 12 , 200 
212 102 . 0 11,800 
213 101.8 12 , 000 
214 102 . 5 11 , 000 
215 101 . 5 12 , 800 
216 102 . 0 13 , 200 
217 102 . 2 12 ,7 50 
218 Challenged 102 . 0 12 , 000 
Data from calf 6120 (continued) 
Virus Isolation from 
Days Temperat ure Leukocytes Titer Nose Rectum Blood Symptoms 
219 102 . 0 1 5 , 000 
220 102 . 0 11,400 + 
221 101. 5 13 , 500 
222 101. 4 13,000 + + 
223 101.8 14,100 
224 1 01.8 16 ,7 00 
225 101. 6 13 , 000 + D 
226 101.8 17,250 D 
227 1 02 . 4 13,7 50 + D 
228 101. 4 15,000 
229 101.4 14,200 
230 101 . 4 13 , 000 + 
231 101.6 12 , 500 
232 101. 2 12,900 4 
f-' 
233 101 . 6 13,400 --4 VJ 
237 102 . 0 13 ,7 50 
239 101. 0 14,ooo 64 
244 101.4 15 , 000 
246 101.8 14 , 200 128 
251 101. 4 13 , 500 
253 101.8 13 , 800 512 
258 101. 6 14 , ooo 
260 101. 0 14,200 512 
D depression 
Data from calf 6127 
Days Temnerature , 
1 1 02 . 4 
2 102 . 2 
3 102 . 7 
4 1 02 . 3 
5 102 . 2 
6 102 . 0 
7 101.7 
8 102. 6 
9 102 . 3 
10 101. 3 
11 102.l 
12 102 . 9 
13 102 . 6 
14 Vacc i nated 102 . 6 
1 5 102 . 6 
1 6 102 . 3 
17 102 . 4 
18 102 . 2 
19 101.2 
20 1 02 . 1 
21 102 . 2 
22 102 . 6 
23 102 . 5 
24 102 . 8 
25 102 . 0 
26 102 . l 
27 102 . 3 
28 101.8 
35 101. 9 
42 2nd Vacci - 102 . 7 
nat i on 
Vaccine - None , Barn Contr ol 
Leukocytes 
14 , 600 
12 ,700 
14 , 700 
13,000 
1 5 , 400 
22 , 000 
ll,600 
10 ,100 
13 , hOO 
12 , 250 
14 , 500 
15 , 500 
10, 900 
11, 750 
11 , 400 
12 , 200 
13 , 400 
12 , 600 
13,100 
11,800 
10 , 500 
10 , 000 
11,600 
10 , 500 
12 , 400 
11,200 
12 , 400 
14,ooo 
1 5, 800 
11 , 500 
Ti ter 
1 
Virus Isolation from 
Nose Rectum Blood Symptoms 
I 
Data from calf 6127 (cont i nued) 
Virus I solation from 
Days Temperature Leukocytes Titer Nose Rectum Blood Symptoms 
49 102.l 13 , 900 
56 102 . 3 17 ' 750 
63 102 . 2 16 , ooo 
70 102 . 2 1 5, 300 
77 102 . 5 12 , 500 
84 101. 9 11 , 500 
91 102 . 0 16 , ooo 
98 102.1 14,500 
105 101.8 16 , 200 
112 101. 9 18 , 300 
119 101. 9 1 5 , 500 
126 102 . 0 14 , ooo 
133 101 . 7 12 , 500 
140 101 . 6 11,250 
147 101. 9 12 , 200 ...... 
154 101.8 11,800 -.l 
Vl 
161 101.8 12 , 250 
168 102 . 0 13 , 500 
175 101.7 12 , 500 
208 101.7 12 , 000 
209 101 . 7 13 , 000 
210 102 . 0 12 , 200 
211 101. 2 11,800 
212 101.8 10 , 600 
213 101.6 11,200 
214 102 . 0 10 , 500 
21 5 101.6 11 , 600 
216 101. 7 10 , 900 
217 101.6 12 , 500 
218 Challenged 1 01.8 11 , 600 
Data from calf 6127 (continued) 
Virus I solation f r om 
Days Temperature Leukocytes Titer Nose Rectum Blood Symptoms 
219 101.8 17 , 000 
220 101.8 11,900 + 
221 101.0 12,000 
222 102 . 6 5 ,700 D 
223 102.0 5 , 300 D 
224 101.4 8 , 200 D, R 
225 101.6 7,300 + D 
226 101. 4 7,500 D 
227 106 . 6 4 '750 + D, A 
228 102 . 2 9 , 500 D, A 
229 101 .8 9 , 400 
230 101. 6 9 , 800 + 
231 101 . 6 8 ,750 
232 101.4 9 , 800 128 
233 101.4 10 , 200 ....... ~ 
237 101. 2 9 , 800 0\ 
239 101.5 9 , 200 256 
244 101. 2 9 , 600 
246 101 . 6 1 0 , 000 512 
251 101. 6 9 , 500 
253 100 . 2 9 , 400 4, 096 
258 102 . 0 9 , 800 
260 101. 4 9 , 500 2 ,048 
D depression 
A anorexia 
R r espiratory (cough) 
Data from calf 6128 Vaccine - None 2 Barn Control 
Virus Isolation from 
Dais TemEerature Leukocytes Titer Nose Rectum Blood s~Etoms 
l 102 . 8 24 , ooo 
2 102 . 2 11, 000 
3 101 . 4 14 , ooo 
4 102 , 4 17 , 500 
5 102 . 6 16 , 500 
6 102 . 0 9 , 000 
1 102 . 8 8 ,700 
8 102 . 4 10,200 
9 102 . 7 10,400 
10 101. 6 10 , 750 
11 102 . 4 13,600 
12 103.1 11,800 
13 101. 8 12 , 200 
14 Vaccinated 102 . 4 11,800 
1 5 102 . 8 11,800 ....... -.1 
16 102 . 4 10 , 200 -.1 
17 1 02 . 2 9,100 
18 102 . 4 11 , 000 
19 102 . 6 14,400 
20 102 . 4 9,800 
21 102 . 3 11 , 750 
22 102 . 5 8 , 250 
23 101.8 10 , 200 
24 102.7 9 , 200 
25 102 . 4 9,900 
26 102 . 4 10 , 000 
27 1 02 . 4 12 , 000 
28 102 . 4 10 , 000 
35 102 . 3 6 , 300 
42 2nd Vacci - 102 . 8 10 , 800 
nation 
Data from calf 6128 (continued) 
Da_ys Temperature 
49 102 . 0 
56 102 . 3 
63 102 . 4 
70 102. 5 
77 102 . 9 
84 102 . 6 
91 101.8 
98 102 . 0 
105 102 . 1 
112 102 . 3 
119 102 . 2 
126 102. 0 
133 102 . 3 
140 102 . 2 
147 102 . 0 
154 102 . 3 
161 102 . 2 
168 102 . 3 
175 102. 0 
208 102 . 3 
209 102 . 2 
210 102 . 1 
211 101. 8 
212 102 . 0 
213 101 . 8 
214 102 . 0 
21 5 101. 6 
216 102 . 0 
217 102 . 0 
218 Challenged 102 .1 
Leukocytes 
1 5 , 400 
12 , 500 
11,600 
9 ,400 
14 , 500 
11,250 
12 , 800 
13 , 500 
12 , 700 
14 , 200 
12 , 800 
12 , 200 
11,600 
12 , 600 
11 , 200 
10 , 200 
10 ,800 
9 , 800 
11 , 000 
12 , 600 
9 , 750 
10 , 600 
11,200 
9 , 750 
9 , 000 
8 , 500 
10 , 000 
11,000 
10 , 750 
9 , 400 
1 
Virus Isolation from 
Titer Nose Rectum Blood SymEtoms 
Data from calf 6128 (continued) 
Virus Isolation from 
Da;ys TemEerature Leukocytes Titer Nose Rectum Bl ood sl'.!!!Etoms 
219 101.6 11 , 250 D, A, E 
220 102 . 0 8 ,7 50 + D, A, E 
221 101. 6 10 , 250 
222 102 . 2 11,800 + 
223 102 . 4 12 ,300 
224 102.2 13 , 800 D,R 
225 101.8 10, 500 + + D 
226 101. 6 6 , 250 D 
227 101.6 5, 450 + + 
228 101.4 7 , 750 
229 101 . 2 1,600 
230 101. 4 6 ,300 
231 101 . 6 9 , 300 
232 101 . 4 10,400 4 + I-' 
233 101.6 9 , 600 --l 
\() 
237 101. 2 10 , 800 + 
239 101. 2 11 , 500 64 
244 101 . 4 10 ,800 
246 101.6 11 , 200 512 
251 101 . 8 12 , 000 
253 102 . 4 11 , 500 2 , 048 
258 101. 4 11,600 
260 101.0 11,400 4,096 
D depression 
A anorexia 
E enteritis 
R respiratory (cough) 
Data from calf 6114 
Days Temperature 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 Vaccinated 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
35 
42 2nd Vacci-
nation 
101. 2 
101. 6 
102 . 6 
102 . 5 
102 . 3 
102 . 4 
102 . 7 
101.9 
102 . 0 
101. 8 
101.7 
102 . 5 
101. 8 
101. 3 
102 . 4 
102 . 2 
102 . 4 
102 . 4 
101. 4 
101.9 
102 . 1 
102 . 2 
102 . 0 
101. 5 
102. 0 
101. 9 
102 . 4 
102 . 5 
101.8 
102 . 1 
Vaccine - None , Barn Control 
Leukocytes 
7 , 500 
14, 500 
24 , ooo 
15 , 400 
22 , 000 
14,ooo 
16 ,750 
14, 500 
16 , 100 
19 , 000 
18 , 200 
21 , 000 
16 ,500 
12 , 200 
12 , 200 
9,600 
10,000 
7,000 
14,100 
12,800 
16 , ooo 
1 5 , 000 
14 , 600 
16 , 500 
1 5 , 250 
13 , 250 
1 5 ,ooo 
1 5 , 900 
14, 500 
14, ooo 
Titer 
Virus Isolation from 
Nose Rectwn Blood Symptoms 
I-' 
()'.) 
0 
Data from calf 6114 (continued) 
Virus Isolation from 
_D.ay~s------~--T_em_p~e_r_a_t_u_r_e _______ Le_uk __ o_c_yt_e_s _____ Ti_t_e_r ____ N_o_s __ e Rectum Bl ood 
49 
56 
63 
70 
77 
84 
91 
98 
105 
ll2 
119 
126 
133 
140 
147 
1 54 
161 
168 
175 
208 
209 
210 
211 
212 
213 
214 
215 
216 
217 
218 Challenged 
102.1 
101.7 
102 . 0 
102 . 7 
102 . 0 
101 . 5 
102 .4 
102 . 2 
102 . 3 
102 . 6 
102 . 5 
102 . 3 
102 . 0 
102 . 2 
102 . 1 
102 . 0 
101.9 
101.7 
101. 9 
101.9 
101.9 
101.7 
101. 8 
101 . 9 
101.7 
101.6 
102 . 0 
101. 6 
101. 4 
101 . 5 
14,500 
21 , 000 
18 , ooo 
22 , 000 
16 , 800 
16 , 500 
19 , 500 
17,500 
16 , 200 
13,000 
15 , 800 
16 , 500 
16 , ooo 
18 , 200 
17 , 600 
1 5 , 900 
1 5 , 000 
17,250 
18 , 500 
18 , ooo 
20 , 750 
18 , 500 
16 ,7 50 
1 5 , 250 
17,250 
1 5 , 500 
13,250 
14,900 
18 , 750 
17 , 500 
Symptoms 
I-' 
O> 
I-' 
l 
I 
Data from calf 6114 (continued) 
Virus Isolation from 
Dals TemEer ature Leukocytes Titer Nose Rectum Blood Sl!,!!Etoms 
219 101.6 22 , 500 
220 101. 6 16 , 500 + 
221 102.0 13, 500 
222 103 . 0 8 , ooo + D 
223 102 . 6 12 ,100 D, E 
224 101. 8 13,800 D, E 
225 103 . 4 9 , 500 + + D,A, E, Bloody & 
Mucous 
226 107 . 4 14,ooo D,A, E,Arched 
Back 
227 102 . 0 22 , 250 + D, A 
228 101.8 16 , 800 
229 101 . 8 14,800 
230 101. 4 13 ,800 + 
231 101.6 14,500 I-' 00 
232 101.0 1 5 , 000 64 + I\) 
233 101 . 8 15 , 800 
237 101.2 16 , 600 
239 101.6 16 , 200 128 
244 101.6 17 ,000 
246 102 . 0 17,600 512 
251 102 . 0 18 , ooo 
253 101.6 17,200 4 , 096 
258 101. 4 16 , 500 
260 101.0 16 , 800 2 , 048 
D depression 
A anorexia 
E enteritis 
.. 
Hanks balanced salt 
NaCl 
KCl 
Mp;S04 . 7H20 
Na 2HP04 . H20 
Glucose 
KH2P04 
CaCl2 
NaHC03 
Earle balanced 
NaCl 
KCl 
MgS04 
NaH2P04 
NaHC03 
Glucose 
CaC12 
salt 
solution 
solution 
La.ctalbumin hydrolysate 
Ea~le basal medium (EBM) : 
NaCl 
KCl 
NaH2P04 . H20 
NaHC03 
1133 
( IIBSS) : 
8 . oo p;ra.ms per liter 
o . 4o " " " 
0 . 20 " " " 
0 .06 " " " 
1. 00 " " " 
0 . 06 " " " 
0 .14 " 11 " 
0 . 35 11 " 11 
( EBSS) : 
6 .80 p:rams per liter 
. 4o " " " 
. 10 " " " 
.125 " " 11 
2 . 20 " " " 
l. 00 " " " 
10. 0 " " " 
5. 0 " " " 
6 . 8 grams per liter 
.4 11 " " 
.14 " " II 
2 . 2 II II II 
50! P'l!1J =;J e n 
184 
Eap;le basal medium (EBM) : (Continued) 
CaCl2 0 . 2 grams per liter 
MQ;Cl2 , 6H20 0,17 " II " 
Glucose 1.0 " II " 
Arp:inine . 021 II II " 
Cystine . 012 " II II 
Histidine . 008 II " II 
Isoleucine . 026 " " " 
Leucine . 026 II " II 
Lysine . 026 II II II 
Methionine . 008 II II " 
Phenylalanine . 016 II " " 
Threonine . 024 " II II 
Tryptophan . 004 " " " 
Tyrosine . 018 II " " 
Valine . 024 II II II 
Glutamine .300 II II II 
Biotin 1. 0 milligrams per liter 
Choline 1. 0 II II II 
Fol ic acid 1. 0 " II II 
Nicotina.mide 1. 0 II II II 
Pantothenic acid 1.0 II " II 
Pyridoxal 1. 0 II II II 
Thiamin 1. 0 II II II 
Riboflavin 0 . 1 II II II 
Phenol red . 04 II II II 
-
f :tli!tJI&'@® ¥1'.l ....-- Y'Cl?C; I TM '1 
185 
GKN solution: 
NaCl B.o grams per liter 
KCl o . 4 " " " 
Glucose 1. 0 " " " 
Trypsin solution: 
Trypsin 2 . 0 P'rwns per liter 
NaCl 8 . o II II II 
KCl o .4 II II II 
Glucose l . O II II If 
NaHC03 o . 84 If If If 
Dulbecco phosphate- buffered saline (PBS) : 
NaCl B.o grams per liter 
KCl 0.2 If If II 
Na2HP04 1.15 II If II 
KH2P04 0 . 2 If II II 
CaCl2 0 .1 II II II 
Mp;Cl 2 . 6H20 0 .1 II " II 
Ammonium and potassium oxalate: 
Ammonium oxalate 1 . 2 p;rams 
Potassium oxalate o . 8 fVamS 
Distilled water q.s. 100 . 0 ml . 
Veronal- buffered saline: 
NaCl lL 5 grams per liter 
Na.- 5 , 5-diethyl barbiturate . 0375 " II II 
mm• s " ZZWF?PP 
186 
Veronal- buffered saline : (Continued) 
5 , 5-diethyl barbituric acid . 0575 grams per liter 
Add 0 . 5 ml of a stock solution containing 1 . 00 M M~Cl2 and 
0 . 30 M CaCl2 • 
-
